Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D231/38—Nitrogen atoms
  • C07D231/42—Benzene-sulfonamido pyrazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
  • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D249/14—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
  • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D257/04—Five-membered rings
  • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D261/14—Nitrogen atoms
  • C07D261/16—Benzene-sulfonamido isoxazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/38—Nitrogen atoms
  • C07D277/50—Nitrogen atoms bound to hetero atoms
  • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
  • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
  • C07D285/135—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• This invention relates to the use of certain compounds as sodium channel blockers and to the treatment of pain by the inhibition of sodium channels. Additionally, this invention relates to novel compounds that are useful as sodium channel blockers.
• Voltage-gated sodium channels are found in all excitable cells including myocytes of muscle and neurons of the central and peripheral nervous system. In neuronal cells sodium channels are primarily responsible for generating the rapid upstroke of the action potential. In this manner sodium channels are essential to the initiation and propagation of electrical signals in the nervous system. Proper and appropriate function of sodium channels is therefore necessary for normal function of the neuron. Consequently, aberrant sodium channel function is thought to underlie a variety of medical disorders (See Hubner CA, Jentsch TJ, Hum. MoI. Genet., 11(20): 2435-45 (2002) for a general review of inherited ion channel disorders) including epilepsy (Yogeeswari et al., Curr.
• VGSC voltage-gated sodium channel
• the Navl .x subfamily can be functionally subdivided into two groups, those which are sensitive to blocking by tetrodotoxin (TTX-sensitive or TTX-s) and those which are resistant to blocking by tetrodotoxin (TTX-resistant or TTX-r).
• TTX-sensitive or TTX-s tetrodotoxin
• TTX-resistant or TTX-r tetrodotoxin
• TTX-resistant sodium channels Navl.8 (SCNlOA, PN3, SNS) and Navl.9 (SCNl IA, NaN, SNS2) are expressed in the peripheral nervous system and show preferential expression in primary nociceptive neurons.
• Human genetic variants of these channels have not been associated with any inherited clinical disorder.
• aberrant expression of Navl.8 has been found in the CNS of human multiple sclerosis (MS) patients and also in a rodent model of MS (Black, JA, et al., Proc. Natl. Acad. ScL USA, 97(21): 11598-602 (2000)).
• the TTX-sensitive subset of voltage-gated sodium channels is expressed in a broader range of tissues than the TTX-resistant channels and has been associated with a variety of human disorders.
• the Na v l.l channel well exemplifies this general pattern, as it is expressed in both the central and peripheral nervous system and has been associated with several seizure disorders including Generalized Epilepsy with Febrile Seizures Plus, types 1 and 2 (GEFS+1, GEFS+2), Severe Myoclonic Epilepsy of Infancy (SMEI), and others (Claes, L, et al., Am. J. Hum. Genet., 68: 1327-1332 (2001); Escayg, A., Am. J. Hum.
• Navl.2 The Navl.2 channel is largely, if not exclusively, expressed in the central nervous system and quantitative studies indicate it is the most abundant VGSC of the CNS. Mutations of Navl.2 are also associated with seizure disorders (Berkovic, S. F., et al, Ann. Neurol, 55: 550-557 (2004)) and Navl.2-null "knockout" mice exhibit perinatal lethality (Planells-Cases R et al, Biophys. J., 78(6):2878-91 (2000)).
• Navl.4 expression of the Navl.4 gene is largely restricted to skeletal muscle and, accordingly, mutations of this gene are associated with a variety of movement disorders (Ptacek, L. J., Am. J. Hum. Genet., 49: 851-854 (1991); Hudson AJ, Brain, 118(2): 547-63 (1995)). The majority of these disorders are related to hyperactivity or "gain-of-function" and have been found to respond to treatment with sodium channel blockers (Desaphy JF, et al, J. Physiol, 554(2): 321-34 (2004)).
• SCN3A nor the SCN8A VGSC genes have been conclusively linked to heritable disorders in humans.
• Loss-of- function mutations of the SCN8A gene are known in mice and yield increasingly debilitating phenotypes, dependent upon the remaining functionality of the gene products (Meisler MH, Genetica, 122(1): 37-45 (2004)).
• Homozygous null mutations cause progressive motor neuron failure leading to paralysis and death, while heterozygous null animals are asymptomatic.
• Homozygous med J mice have nearly 90% reduction in functional Navl.6 current and exhibit dystonia and muscle weakness but are still viable.
• Navl .6 is expressed at high levels in dorsal root ganglia and can be found in spinal sensory tracts (Tzoumaka E, J. Neurosci. Res., 60(1): 37-44 (2000)). It should be noted however that expression of Navl .6 is not restricted to sensory neurons of the periphery. Like the Navl .6 channel, expression of the Navl.3 VGSC can also be detected in both the central and peripheral nervous system, though levels in the adult CNS are generally much higher than PNS.
• Navl .3 During development and the early postnatal period Navl .3 is expressed in peripheral neurons but this expression wanes as the animal matures (Shah BS, J. Physiol, 534(3): 763-76 (2001); Schaller KL, Cerebellum, 2(1): 2-9 (2003)). Following neuronal insult Navl.3 expression is upregulated, more closely mimicking the developmental expression patterns (Hains BC, J. Neurosci., 23(26): 8881-92 (2003)). Coincident with the recurrence of Navl.3 expression is the emergence of a rapidly re -priming sodium current in the injured axons with a biophysical profile similar to Navl .3 (Leffier A, et al, J.
• the Na v 1.7 (PN 1 , SCN9A) VGSC is sensitive to blocking by tetrodotoxin and is preferentially expressed in peripheral sympathetic and sensory neurons.
• the SCN9A gene has been cloned from a number of species, including human, rat, and rabbit and shows ⁇ 90 % amino acid identity between the human and rat genes (Toledo-Aral et al., Proc. Natl. Acad. Sci. USA, 94(4): 1527-1532 (1997)).
• Na v l .7 may play a key role in various pain states, including acute, inflammatory and/or neuropathic pain.
• Na v 1.7 protein has been shown to accumulate in neuromas, particularly painful neuromas (Kretschmer et al., Acta. Neurochir. (Wien), 144(8): 803-10 (2002)).
• Sodium channel-blocking agents have been reported to be effective in the treatment of various disease states, and have found particular use as local anesthetics and in the treatment of cardiac arrhythmias. It has also been reported that sodium channel-blocking agents may be useful in the treatment of pain, including acute, chronic, inflammatory and/or neuropathic pain; see, for example, Wood, JN et al., J. Neurobiol., 61(1): 55-71 (2004). Preclinical evidence demonstrates that sodium channel-blocking agents can suppress neuronal firing in peripheral and central sensory neurons, and it is via this mechanism that they may be useful for relieving pain. In some instances abnormal or ectopic firing can originate from injured or otherwise sensitized neurons.
• sodium channels can accumulate in peripheral nerves at sites of axonal injury and may function as generators of ectopic firing (Devor et al. J. Neurosci., 132: 1976 (1993)). Changes in sodium channel expression and excitability have also been shown in animal models of inflammatory pain where treatment with proinflammatory materials (CFA, Carrageenan) promoted pain-related behaviors and correlated with increased expression of sodium channel subunits (Gould et al., Brain Res., 824(2): 296-9 (1999); Black et al, Pain, 108(3): 237-47 (2004)). Alterations in either the level of expression or distribution of sodium channels, therefore, may have a major influence on neuronal excitability and pain-related behaviors.
• CFA proinflammatory material
• Ohkawa et al. have described a class of cyclic ethers that are of use as sodium channel blockers (U.S. Patent No. 6,172,085).
• the present invention provides compounds that are useful in the treatment of diseases through the modulation of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides compounds, compositions and methods that are useful in ameliorating or alleviating conditions susceptible to such ion channel modulation as more fully described below.
• CHO means Chinese hamster ovary
• HEK means human embryonic kidney
• EBSS means Earl's Balanced Salt Solution
• SDS means sodium dodecyl sulfate
• Et 3 N means triethylamine
• CDI means N 5 N'- carbonyldiimidazole
• HCl means l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride
• DCC means N,N'-dicyclohexylcarbodiimide
• HOAT means l-hydroxy-7-azabenzotriazole
• HOBT means 1-hydroxybenzotriazole hydrate
• HBTU means O-benzotriazol-l-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate
• TBTU means O- (
• V ⁇ S whether utilized as a bond or displayed perpendicular to a bond, indicates the point at which the displayed moiety is attached to the remainder of the molecule.
• the symbol S whether utilized as a bond or displayed perpendicular to a bond, indicates the point at which the displayed moiety is attached to the carbon atom of a carbonyl moiety.
• Bio medium refers to both in vitro and in vivo biological milieus.
• exemplary in vitro “biological media” include, but are not limited to, cell culture or extracts thereof, tissue culture or extracts thereof, homogenates or extracts thereof, biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
• In vivo applications are generally performed in mammals, preferably humans.
• Somatic pain refers to a normal nerve response to a noxious stimulus such as injury or illness, e.g., trauma, burn, infection, inflammation, or disease process such as cancer, and includes both cutaneous pain (e.g., skin, muscle or joint derived) and visceral pain (e.g., organ derived).
• a noxious stimulus such as injury or illness, e.g., trauma, burn, infection, inflammation, or disease process such as cancer
• cutaneous pain e.g., skin, muscle or joint derived
• visceral pain e.g., organ derived
• Inhibiting and blocking are used interchangeably herein to refer to the partial or full blockade of a voltage sodium gated channel by a compound of the invention, which leads to a decrease in ion flux either into or out of a cell in which a voltage-gated sodium channel is found.
• the compounds of the invention and/or formula (I), being sodium channel modulators, are potentially useful in the treatment of a range of disorders.
• the treatment of pain, particularly neuropathic pain and/or inflammatory pain, is a preferred use.
• Physiological pain is an important protective mechanism designed to warn of danger from potentially injurious stimuli from the external environment.
• the system operates through a specific set of primary sensory neurones and is activated by noxious stimuli via peripheral transducing mechanisms (see Millan, 1999, Prog. Neurobiol., 57, 1-164 for a review).
• These sensory fibres are known as nociceptors and are characteristically small diameter axons with slow conduction velocities. Nociceptors encode the intensity, duration and quality of noxious stimulus and by virtue of their topographically organized projection to the spinal cord, the location of the stimuli.
• nociceptive nerve fibres of which there are two main types, A-delta fibres (myelinated) and C fibres (non-myelinated).
• A-delta fibres myelinated
• C fibres non-myelinated
• the activity generated by nociceptor input is transferred, after complex processing in the dorsal horn, either directly, or via brain stem relay nuclei, to the ventrobasal thalamus and then on to the cortex, where the sensation of pain is generated.
• Pain may generally be classified as acute or chronic. Acute pain begins suddenly and is short-lived (usually twelve weeks or less). It is usually associated with a specific cause such as a specific injury and is often sharp and severe.
• Acute pain does not generally result in any persistent psychological response.
• chronic pain is long-term pain, typically persisting for more than three months and leading to significant psychological and emotional problems.
• Common examples of chronic pain are neuropathic pain (e.g. painful diabetic neuropathy, postherpetic neuralgia), carpal tunnel syndrome, back pain, headache, cancer pain, arthritic pain and chronic post-surgical pain.
• Clinical pain is present when discomfort and abnormal sensitivity feature among the patient's symptoms. Patients tend to be quite heterogeneous and may present with various pain symptoms. Such symptoms include: 1) spontaneous pain which may be dull, burning, or stabbing; 2) exaggerated pain responses to noxious stimuli (hyperalgesia); and 3) pain produced by normally innocuous stimuli (allodynia - Meyer et al., 1994, Textbook of Pain, 13- 44). Although patients suffering from various forms of acute and chronic pain may have similar symptoms, the underlying mechanisms may be different and may, therefore, require different treatment strategies. Pain can also therefore be divided into a number of different subtypes according to differing pathophysiology, including nociceptive, inflammatory and neuropathic pain.
• Nociceptive pain is induced by tissue injury or by intense stimuli with the potential to cause injury. Pain afferents are activated by transduction of stimuli by nociceptors at the site of injury and activate neurons in the spinal cord at the level of their termination. This is then relayed up the spinal tracts to the brain where pain is perceived (Meyer et al., 1994, Textbook of Pain, 13-44). The activation of nociceptors activates two types of afferent nerve fibres. Myelinated A-delta fibres transmit rapidly and are responsible for sharp and stabbing pain sensations, whilst unmyelinated C fibres transmit at a slower rate and convey a dull or aching pain.
• Moderate to severe acute nociceptive pain is a prominent feature of pain from central nervous system trauma, strains/sprains, burns, myocardial infarction and acute pancreatitis, post-operative pain (pain following any type of surgical procedure), posttraumatic pain, renal colic, cancer pain and back pain.
• Cancer pain may be chronic pain such as tumor related pain (e.g. bone pain, headache, facial pain or visceral pain) or pain associated with cancer therapy (e.g. postchemotherapy syndrome, chronic postsurgical pain syndrome or post radiation syndrome). Cancer pain may also occur in response to chemotherapy, immunotherapy, hormonal therapy or radiotherapy.
• Back pain may be due to herniated or ruptured intervertabral discs or abnormalities of the lumber facet joints, sacroiliac joints, paraspinal muscles or the posterior longitudinal ligament. Back pain may resolve naturally but in some patients, where it lasts over 12 weeks, it becomes a chronic condition which can be particularly debilitating.
• Neuropathic pain is currently defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system. Nerve damage can be caused by trauma and disease and thus the term 'neuropathic pain' encompasses many disorders with diverse aetiologies. These include, but are not limited to, peripheral neuropathy, diabetic neuropathy, post herpetic neuralgia, trigeminal neuralgia, back pain, cancer neuropathy, HIV neuropathy, phantom limb pain, carpal tunnel syndrome, central post-stroke pain and pain associated with chronic alcoholism, hypothyroidism, uremia, multiple sclerosis, spinal cord injury, Parkinson's disease, epilepsy and vitamin deficiency. Neuropathic pain is pathological as it has no protective role.
• neuropathic pain are difficult to treat, as they are often heterogeneous even between patients with the same disease (Woolf & Decosterd, 1999, Pain Supp., 6, S141-S147; Woolf and Mannion, 1999, Lancet, 353, 1959-1964). They include spontaneous pain, which can be continuous, and paroxysmal or abnormal evoked pain, such as hyperalgesia (increased sensitivity to a noxious stimulus) and allodynia (sensitivity to a normally innocuous stimulus).
• the inflammatory process is a complex series of biochemical and cellular events, activated in response to tissue injury or the presence of foreign substances, which results in swelling and pain (Levine and Taiwo, 1994, Textbook of Pain, 45-56).
• Arthritic pain is the most common inflammatory pain.
• Rheumatoid disease is one of the commonest chronic inflammatory conditions in developed countries and rheumatoid arthritis is a common cause of disability.
• the exact aetiology of rheumatoid arthritis is unknown, but current hypotheses suggest that both genetic and microbiological factors may be important (Grennan & Jayson, 1994, Textbook of Pain, 397-407).
• Visceral pain is pain associated with the viscera, which encompass the organs of the abdominal cavity. These organs include the sex organs, spleen and part of the digestive system. Pain associated with the viscera can be divided into digestive visceral pain and non-digestive visceral pain.
• GI gastrointestinal
• BBD functional bowel disorder
• IBD inflammatory bowel disease
• GI disorders include a wide range of disease states that are currently only moderately controlled, including, in respect of FBD, gastro -esophageal reflux, dyspepsia, irritable bowel syndrome (IBS) and functional abdominal pain syndrome (FAPS), and, in respect of IBD, Crohn's disease, ileitis and ulcerative colitis, all of which regularly produce visceral pain.
• Other types of visceral pain include the pain associated with dysmenorrhea, cystitis and pancreatitis and pelvic pain.
• heart and vascular pain including pain caused by angina, myocardical infarction, mitral stenosis, pericarditis, Raynaud's phenomenon, scleredoma and skeletal muscle ischemia;
• head pain such as migraine (including migraine with aura and migraine without aura), cluster headache, tension-type headache mixed headache and headache associated with vascular disorders; and
• orofacial pain including dental pain, otic pain, burning mouth syndrome and temporomandibular myofascial pain.
• substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents, which would result from writing the structure from right to left, e.g. , -CH 2 O- is preferably intended to also recite -OCH 2 -.
• alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight- or branched-chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di- and multivalent radicals, having the number of carbon atoms designated (i.e. C 1 -C 10 means one to ten carbons).
• saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n- pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
• An unsaturated alkyl group is one having one or more double bonds or triple bonds.
• alkyl groups examples include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4- pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
• alkyl unless otherwise noted, also preferably include those derivatives of alkyl defined in more detail below, such as “heteroalkyl.” Alkyl groups that are limited to hydrocarbon groups are termed "homoalkyl".
• alkyl refers to alkyl, alkenyl and alkynyl moieties, each of which can be mono-, di- or polyvalent species. Alkyl groups are preferably substituted, e.g., with one or more group referred to hereinbelow as an "alkyl group substituent.”
• alkylene by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by -CH 2 CH 2 CH 2 CH 2 -, and further includes those groups described below as “heteroalkylene.”
• an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
• a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
• alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
• heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight- or branched-chain, or cyclic alkyl radical consisting of the stated number of carbon atoms and at least one heteroatom selected from the group consisting of B, O, N, Si and S, wherein the heteroatom may optionally be oxidized and the nitrogen atom may optionally be quaternized.
• the heteroatom(s) may be placed at any internal position of the heteroalkyl group or at a terminus of the chain, e.g., the position through which the alkyl group is attached to the remainder of the molecule.
• heteroalkylene by itself or as part of another substituent refers to a substituted or unsubstituted divalent heteroalkyl radical, as exemplified, but not limited by, -CH 2 -CH 2 -S- CH 2 -CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
• heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O) 2 R'- represents-C(O) 2 R'- and, preferably, -R 5 C(O) 2 -.
• cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
• heterocycloalkyl examples include, but are not limited to, 1 -(1,2,5,6- tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1 - piperazinyl, 2-piperazinyl, and the like.
• halo or halogen
• haloalkyl by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
• terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl.
• halo(Ci-C 4 )alkyl is mean to include, but not be limited to, trifluoromethyl, 2,2,2- trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
• aryl means, unless otherwise stated, a polyunsaturated, aromatic, substituent that can be a single ring or multiple rings (preferably from 1 to 3 rings, one or more of which is optionally a cycloalkyl or heterocycloalkyl), which are fused together or linked covalently.
• heteroaryl refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
• Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2- pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4- thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2- pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-is
• aryl when used in combination with other terms (e.g. , aryloxy, arylthioxy, arylalkyl) preferably includes both homoaryl and heteroaryl rings as defined above.
• arylalkyl optionally includes those radicals in which an aryl group is attached to an alkyl group (e.g.
• benzyl, phenethyl, pyridylmethyl and the like including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l-naphthyloxy)propyl, and the like).
• a carbon atom e.g., a methylene group
• an oxygen atom e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l-naphthyloxy)propyl, and the like.
• R', R", R'", R"" and R'" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g. , aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups.
• each of the R groups is independently selected as are each R', R", R'", R"" and R'"" groups when more than one of these groups is present.
• R' and R" When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7- membered ring.
• -NR'R is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl.
• alkyl includes groups with carbon atoms bound to groups other than hydrogen, such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g., -C(O)CH 3 , -C(O)CF 3 , - C(O)CH 2 OCH 3 , and the like).
• substituents for the aryl and heteroaryl groups are generically referred to as "aryl group substituents.”
• Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR') q -U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer from 0 to 3.
• two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) I -B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O) 2 -, -S(O) 2 NR'- or a single bond, and r is an integer of from 1 to 4.
• One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
• two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CRR') S - X-(CR"R'")d-, where s and d are independently integers of from 0 to 3, and X is -O-, -NR'-, - S-, -S(O)-, -S(O) 2 -, or -S(O) 2 NR'-.
• the substituents R, R', R" and R'" are preferably independently selected from hydrogen or substituted or unsubstituted (Ci-Ce)alkyl.
• heteroatom includes oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
• R is a general abbreviation that represents a substituent group that is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl groups.
• salt(s) includes salts of the compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
• base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
• base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
• acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
• acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, butyric, maleic, malic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
• inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous
• salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al, Journal of Pharmaceutical Science, 66: 1-19 (1977)).
• Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
• the salt is preferably a pharmaceutically acceptable salt.
• pharmaceutically acceptable salts are presented hereinabove, and are generally known in the art. See, for example, Wermuth, C, PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE- A HANDBOOK, Verlag Helvetica Chimica Acta (2002)
• the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
• the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
• the present invention provides compounds that are in a prodrug form.
• Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention.
• prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
• prodrug means a derivative of a compound that can hydro lyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide the compound.
• prodrugs include, but are not limited to, compounds that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
• Other examples of prodrugs include compounds that comprise NO, NO 2 , -ONO, or -ONO 2 moieties.
• prodrug is accorded a meaning herein such that prodrugs do not encompass the parent compound of the prodrug.
• prodrug may also to be interpreted to exclude other compounds of the invention.
• biohydrolyzable carbamate As used herein, and unless otherwise indicated, the terms “biohydrolyzable carbamate,” “biohydrolyzable carbonate,” “biohydrolyzable ureide” and “biohydrolyzable phosphate” mean a carbamate, carbonate, ureide and phosphate, respectively, of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted in vivo to the biologically active compound.
• biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, aminoacids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
• biohydrolyzable ester means an ester of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted in vivo to the biologically active compound.
• biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters.
• biohydrolyzable amide means an amide of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted in vivo to the biologically active compound.
• biohydrolyzable amides include, but are not limited to, lower alkyl amides, ⁇ -amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
• Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
• Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.
• composition that is "substantially free" of a compound means that the composition contains less than about 20% by weight, more preferably less than about 10% by weight, even more preferably less than about 5% by weight, and most preferably less than about 3% by weight of the compound.
• the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
• the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine- 125 ( 125 I) or carbon- 14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
• the invention is a compound described herein.
• the invention is according to a formula described herein.
• the compound has a formula according to Formula I:
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl and substituted or unsubstituted aryl; with the proviso that R 5 and R 6 are not both hydrogen; with the further proviso that R 5 and R 6 , when taken together with the nitrogen to which they are attached, are optionally joined to form a substituted or unsubstituted 4- to 8- membered heterocycloalkyl ring; B is a member selected from substituted or unsubstituted aryl and substituted or unsubstituted 6-membered heteroaryl; and Z is a substituted or unsubstituted 5-membered heteroaryl.
• the compound of formula (I) is not one of the following: N-(5-methyl-3-isoxazolyl)-3-[[(5-methyl-3- isoxazolyl)amino]sulfonyl]-benzamide; 3-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]-N- 1,3,4- thiadiazol-2-yl-benzamide; N-(5-ethyl-l,3,4-thiadiazol-2-yl)-3-(4-morpholinylcarbonyl)- benzenesulfonamide; 1 -[3-[[[5-(1 , 1 -dimethylethyl)-4-methyl-2- thiazolyl]amino]sulfonyl]benzoyl] piperidine; N-(5-methyl-l,3,4-thiadiazol-2-yl)-3-(4-
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted arylalkyl, substituted or unsubstituted (heteroaryl)alkyl, substituted or unsubstituted (heterocycloalkyl)alkyl and substituted or unsubstituted (cycloalkyl)alkyl.
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted aryl(Ci-C4)alkyl, substituted or unsubstituted heteroaryl(Ci-C 4 )alkyl, substituted or unsubstituted heterocycloalkyl(Ci-C 4 )alkyl and substituted or unsubstituted cycloalkyl(Ci-C 4 )alkyl.
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted aryl(d-C 2 )alkyl, substituted or unsubstituted heteroaryl(Ci-C2)alkyl, substituted or unsubstituted heterocycloalkyl(Ci-C 2 )alkyl and substituted or unsubstituted cycloalkyl(Ci-C 2 )alkyl.
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted aryloxy, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted (heterocycloalkyl)oxy and substituted or unsubstituted (cycloalkyl)oxy.
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted aryloxyalkyl, substituted or unsubstituted heteroaryloxyalkyl, substituted or unsubstituted heterocycloalkyloxyalkyl and substituted or unsubstituted cycloalkyloxyalkyl.
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted aryloxy(Ci-C4)alkyl, substituted or unsubstituted heteroaryloxy(C i -C4)alkyl, substituted or unsubstituted heterocycloalkyloxy(C i - C 4 )alkyl and substituted or unsubstituted cycloalkyloxy(Ci-C 4 )alkyl.
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted aryloxy(Ci-C 2 )alkyl, substituted or unsubstituted heteroaryloxy(Ci-C 2 )alkyl, substituted or unsubstituted heterocycloalkyloxy(Ci-C2)alkyl and substituted or unsubstituted cycloalkyloxy(C i -C 2 )alkyl.
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted arylaminoalkyl and substituted or unsubstituted heteroarylaminoalkyl. In an exemplary embodiment, R 5 and R 6 are each members independently selected from H, substituted or unsubstituted arylamino(Ci-C 4 )alkyl and substituted or unsubstituted heteroarylamino(Ci-C 4 )alkyl.
• R 5 and R 6 are each members independently selected from H, substituted or unsubstituted arylamino(Ci-C 2 )alkyl and substituted or unsubstituted heteroarylamino(Ci-C 2 )alkyl.
• R 5 is a member selected from H, substituted or unsubstituted (Ci-Cio)alkyl and substituted or unsubstituted (C3-C8)cycloalkyl. In an exemplary embodiment, R 5 is H. In an exemplary embodiment, R 5 is a member selected from substituted or unsubstituted (Ci-Cio)alkyl and substituted or unsubstituted (C 3 -Cg)cycloalkyl. In an exemplary embodiment, R 5 is a member selected from (Ci-C 4 )alkyl, hydroxy (C 1 -
• C 4 )alkyl cyano (Ci-C 4 )alkyl, (C 3 -Cg)cycloalkyl, phenyl(Ci-C 4 )alkyl, hydroxycyclohexyl and hy droxy alky Icy clohexyl.
• R 5 is a member selected from methyl, ethyl, isopropyl, propyl, n-butyl, t-butyl, hydroxymethyl, hydroxypropyl, hydroxybutyl, hydroxyethyl, cyanomethyl, cyanoethyl, cyanopropyl, cyanoisopropyl, cyanobutyl, 2-hydroxy- 1-phenylethyl, cyclopropyl, cyclopentyl, cyclohexyl, (IR, 2R) 2-hy droxy cyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2S) (2-hydroxymethyl)cyclohexyl and (IS, 2R) (2- hydroxymethyl)cyclohexyl.
• R 5 is a member selected from methyl, ethyl, isopropyl, hydroxyethyl, cyanoethyl, 2 -hydroxy- 1-phenylethyl, cyclopropyl, cyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2S) (2- hydroxymethyl)cyclohexyl and (IS, 2R) (2-hydroxymethyl)cyclohexyl.
• R 6 is H
• R 5 is a member selected from substituted or unsubstituted (Ci-Cio)alkyl and substituted or unsubstituted (C3-C8)cycloalkyl.
• R 6 is H
• R 5 is a member selected from (Ci-C 4 )alkyl, hydroxy (C 1 - C 4 )alkyl, cyano (Ci-C 4 )alkyl, (C 3 -C 8 )cycloalkyl, phenyl(d-C 4 )alkyl and hydroxycyclohexyl and hydroxy alky Icy clohexyl.
• R 6 is H
• R 5 is a member selected from methyl, ethyl, isopropyl, propyl, n-butyl, t-butyl, hydroxymethyl, hydroxypropyl, hydroxybutyl, hydroxyethyl, cyanomethyl, cyanoethyl, cyanopropyl, cyanoisopropyl, cyanobutyl, 2-hydroxy-l-phenylethyl, cyclopropyl, cyclopentyl, cyclohexyl, (IR, 2R) 2- hydroxycyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2S) (2-hydroxymethyl)cyclohexyl and (IS, 2R) (2-hydroxymethyl)cyclohexyl.
• R 6 is H
• R 5 is a member selected from methyl, ethyl, isopropyl, hydroxyethyl, cyanoethyl, 2-hydroxy-l- phenylethyl, cyclopropyl, cyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2R) 2- hydroxycyclohexyl, (IR, 2S) (2-hydroxymethyl)cyclohexyl, (IS, 2R) (2- hydroxymethyl)cyclohexyl.
• R 6 is not H, and R 5 is a member selected from substituted or unsubstituted (Ci-Cio)alkyl and substituted or unsubstituted (C3-C8)cycloalkyl.
• R 6 is not H, and R 5 is a member selected from (Ci-C 4 )alkyl, hydroxy (d-C 4 )alkyl, cyano (d-C 4 )alkyl, (C 3 -C 8 )cycloalkyl, phenyl(d-C 4 )alkyl and hydroxy cyclohexyl and hy droxy alky Icy clohexyl.
• R 6 is not H
• R 5 is a member selected from methyl, ethyl, isopropyl, propyl, n-butyl, t-butyl, hydroxymethyl, hydroxypropyl, hydroxybutyl, hydroxyethyl, cyanomethyl, cyanoethyl, cyanopropyl, cyanoisopropyl, cyanobutyl, 2-hydroxy-l-phenylethyl, cyclopropyl, cyclopentyl, cyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2S) (2- hydroxymethyl)cyclohexyl and (IS, 2R) (2-hydroxymethyl)cyclohexyl.
• R 6 is not H, and R 5 is a member selected from methyl, ethyl, isopropyl, hydroxyethyl, cyanoethyl, 2-hydroxy-l-phenylethyl, cyclopropyl, cyclohexyl, (IR, 2R) 2- hydroxycyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2S) (2-hydroxymethyl)cyclohexyl and (IS, 2R) (2-hydroxymethyl)cyclohexyl.
• R 6 is substituted or unsubstituted benzyl
• R 5 is a member selected from substituted or unsubstituted (Ci-Cio)alkyl and substituted or unsubstituted (C 3 -C 8 )cycloalkyl.
• R 6 is substituted or unsubstituted benzyl
• R 5 is a member selected from (Ci-C 4 )alkyl, hydroxy(Ci-C 4 )alkyl, cyano (Ci-C 4 )alkyl, (C 3 -C 8 )cycloalkyl, phenyl(d-C 4 )alkyl, hydroxycyclohexyl and hydroxy alky Icy clohexyl.
• R 6 is substituted or unsubstituted benzyl
• R 5 is a member selected from methyl, ethyl, isopropyl, propyl, n-butyl, t-butyl, hydroxymethyl, hydroxypropyl, hydroxybutyl, hydroxyethyl, cyanomethyl, cyanoethyl, cyanopropyl, cyanoisopropyl, cyanobutyl, 2-hydroxy-l-phenylethyl, cyclopropyl, cyclopentyl, cyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2S) (2- hydroxymethyl)cyclohexyl and (IS, 2R) (2-hydroxymethyl)cyclohexyl.
• R 6 is substituted or unsubstituted benzyl
• R 5 is a member selected from methyl, ethyl, isopropyl, hydroxyethyl, cyanoethyl, 2-hydroxy-l-phenylethyl, cyclopropyl, cyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2S) (2- hydroxymethyl)cyclohexyl and (IS, 2R) (2-hydroxymethyl)cyclohexyl.
• R 5 is methyl, and R 6 is substituted or unsubstituted benzyl.
• R 5 is methyl, and R 6 is a member selected from
• R 5 is methyl
• R 6 is a member selected from (halo)benzyl and (trihalo(Ci-C 4 )alkyl)benzyl.
• R 5 is methyl
• R 6 is a member selected from (fluoro)benzyl, chlorobenzyl and (trifluoro(Ci-C 4 )alkyl)benzyl.
• R 5 is methyl
• R 6 is a member selected from (trifluoromethyl)benzyl, (trifluoroethyl)benzyl and (trifluoropropyl)benzyl.
• R 5 is methyl
• R 6 is a member selected from (4-halo)benzyl, (3- trihalo(Ci-C 4 )alkyl)benzyl and (4-trihalo(Ci-C 4 )alkyl)benzyl.
• R 5 is methyl
• R 6 is a member selected from (4-fluoro)benzyl, (3-trifluoro(Ci-C 4 )alkyl)benzyl and (4-trifluoro(Ci-C 4 )alkyl)benzyl.
• R 5 is methyl
• R 6 is a member selected from (4-fluoro)benzyl, (3-trifluoromethyl)benzyl and (4- trifluoromethyl)benzyl.
• R 5 is methyl, and R 6 is substituted or unsubstituted phenylpropyl.
• R 5 is methyl, and R 6 is hydroxyphenylpropyl.
• R 5 is methyl, and R 6 is 3-hydroxy-3-phenylpropyl.
• R 5 is a member selected from ethyl and methyl
• R 6 is a member selected from substituted or unsubstituted 1-phenylethyl and substituted or unsubstituted 2-phenylethyl.
• R 5 is a member selected from ethyl and methyl
• R 6 is a member selected from hydroxy-2-phenylethyl, diphenylethyl and (hydroxy(Ci-C 4 )alkyl)-2-phenylethyl.
• R 5 is a member selected from ethyl and methyl
• R 6 is is a member selected from 1 ,2-diphenylethyl, 2-hydroxy-2- phenylethyl, (IS)- 1-phenylethyl, 2-oxo-l-methyl-2-phenylethyl and 2-hydroxy-l-methyl-2- phenylethyl.
• R 5 is methyl
• R 6 is a member selected from ((lS,2R)-2-hydroxy-l-methyl-2-phenylethyl and (lS)-l-phenylethyl.
• R 5 is ethyl
• R 6 is l-methyl-2-oxo-2-phenylethyl.
• R 5 is ethyl
• R 6 is 2-hydroxy-l-phenylethyl.
• R 5 is ethyl
• R 6 is a member selected from 1 ,2-diphenylethyl, 2-hydroxy-2-phenylethyl and ( 1 S)-2-hydroxy- 1 -phenylethyl.
• R 5 is a member selected from (IR, 2R) 2- hydroxycyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2S) (2-hydroxymethyl)cyclohexyl, (IS, 2R) (2-hydroxymethyl)cyclohexyl, and R 6 is substituted or unsubstituted benzyl.
• R 5 is isopropyl, and R 6 is substituted or unsubstituted benzyl. In an exemplary embodiment, R 5 is isopropyl, and R 6 is unsubstituted benzyl.
• R 5 is cyclopropyl, and R 6 is substituted or unsubstituted benzyl.
• R 5 is cyclopropyl, and R 6 is (halo)benzyl.
• R 5 is cyclopropyl, and R 6 is (4-halo)benzyl.
• R 5 is cyclopropyl, and R 6 is (4-fluoro)benzyl.
• R 5 and R 6 along with the nitrogen atom to which they are both attached, are joined to form a substituted or unsubstituted 5 to 8 membered ring.
• R 5 and R 6 along with the nitrogen atom to which they are both attached, have a structure according to the following formula:
• dotted line encircling Q comprises the atoms necessary for the formation of one ring to three fused rings having 4 to 9 atoms in each ring.
• the symbol w is an integer selected from 0 to the number of atoms necessary for the formation of Q.
• Each R 13 is a member independently selected from H, cyano, hydroxyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted (Ci-Cio)alkyl, substituted or unsubstituted (C 1 - Cio)alkoxy and substituted or unsubstituted (C3-C8)cycloalkyl.
• Each R 13 is a member independently selected from H, cyano, hydroxyl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, substituted or unsubstituted (Ci-C4)alkyl and substituted or unsubstituted (Ci-C 4 )alkoxy.
• each R 13 is a member independently selected from H, cyano, hydroxyl, halophenyl, (alkyl)phenyl, dialkylphenyl, (alkoxy)phenyl, halobenzyl, hydroxyl, pyrazolyl, phenoxy, (alkyl)phenoxy, (halo)phenoxy, (halo)(alkyl)phenoxy, methyl, cyano(halo)phenoxy, (halo)alkylphenyl, (alkoxy)benzyl, benzyl, (halo)(alkoxy)benzyl, (alkoxy)phenoxy, substituted or unsubstituted isoindolyl, 1,3 dihydroisoindolyl, benzyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted pyrimidinyl, (alkyl)pyridimidinyl, (substituted or unsub
• each R 13 is a member selected from 2- chlorophenyl, 3-fluorobenzyl, phenyl, methyl, phenoxymethyl, hydroxy, fluorobenzyl, 3- methylphenoxy, 3-methylphenyl, lH-pyrazolyl, cyano(fluoro)phenoxy, fluoro(methyl)phenyl, chlorophenyl, 2-methoxybenzyl, benzyl, 2-methylphenoxy, 3-fluoro-4-methoxybenzyl, 2- chlorophenoxy, 3-methoxyphenyl, 2,5-dimethylphenyl, 4-methoxyphenoxy, 2-methylphenoxy, 4-methoxybenzyl, 4-methylphenyl, l-oxo-l,3-dihydro-2H-isoindol-2-yl, 3-benzyloxy, 2- methylpyrimidin-4-yl, 5-fluoropyridin-2-yl, 3-methoxyphenyl, 3 -
• Q is a member selected from (4aR,9aS)-2,3,9,9a- tetrahydroindeno[2, 1 -b] [ 1 ,4]oxazin-4(4aH)yl, (4aS,9aR)-2,3,9,9a-tetrahydroindeno[2, 1 - b][l,4]oxazin-4(4aH)yl, (5-chloro)3,4-dihydroisoquinolinyl, dihydroisoquinolinyl, (5-chloro)- l,3dihydro-2H-isoindolyl, (4-chloro)-l,3dihydro-2H-isoindolyl and (3S, 3aR, 6R, 7aS)-8-oxo- 2-phenyloctahydro- 1 H-3 ,6-methanoindolyl.
• said R 5 and R 6 along with the nitrogen atom to which they are both attached, is a member selected from substituted or unsubstituted thiomorpholinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted oxazepanyl, substituted or unsubstituted oxazinanyl, substituted or unsubstituted azepanyl and substituted or unsubstituted piperazinyl.
• said R 5 and R 6 along with the nitrogen atom to which they are both attached, is a member selected from substituted or unsubstituted 1 ,4 oxazepanyl and substituted or unsubstituted 1,3 oxazinanyl.
• said R 5 and R 6 along with the nitrogen atom to which they are both attached, is a member selected from unsubstituted thiomorpholinyl, (2- chlorophenyl)thiomorpholinyl, (3 -fluorobenzyl)piperidinyl, (3 -phenyl)morpholinyl, methyl(phenoxymethyl)pyrrolidinyl), hydroxy(fluorobenzyl)l ,4-oxazepanyl, (3- methylphenoxy)piperidinyl, methyl(3-methylphenyl)morpholinyl, (lH-pyrazolyl)ethyl,
• R is a member selected from
• each R 10 is a member independently selected from halogen, cyano, hydroxyl, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C 3 -Cs cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl and trifluoromethylthio;
• R 1Oa is a member selected from H, (Ci-C 4 )alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted benzyl;
• R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are each members independently selected from H, halogen, cyano, hydroxyl, substituted or unsubstituted Ci-C 4 alkyl, substituted or unsubstituted C 3 -Cs cycloalkyl, substituted or unsubstituted C 3 -Cs heterocycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio, substituted or unsubstituted pyrazolyl, substituted or unsubstituted heteroaryl Ci -C 4 alkyl; with the proviso that R 7 and R 7a are optionally joined with C* to form a member selected from a carbonyl and substituted and unsubstituted 3- to 7-membered ring; with the further proviso that R 8 and R 8a are optionally joined with C** to
• each R 10 are optionally joined, along with the atoms to which they are attached, to form a 3- to 7-membered ring.
• R 10 is substituted or unsubstituted pyrazolyl.
• R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are each members independently selected from H, hydroxy, 2-hydroxyethyl, methyl, (S)-methyl, (R)-methyl, cyclopropyl, substituted or unsubstituted isoxazol-5-yl, (substituted or unsubstituted Ci-C 4 alkyl) isoxazol-5-yl, methyl isoxazol-5-yl, 3-methyl isoxazol-5-yl, halogen, cyano, hydroxyl, substituted or unsubstituted Ci-C 4 alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or unsubstituted pyrazolyl.
• R and R , 7a a are joined with C* to form a carbonyl.
• R and R , 7a a are joined with C* to form a member selected from substituted or unsubstituted cyclopropyl and substituted or unsubstituted cyclopentyl, and wherein C* has a configuration which is a member selected from R and S.
• R 8 and R 8a are joined with C** to form a member selected from substituted or unsubstituted cyclopropyl and wherein C** has a configuration which is a member selected from R and S.
• R 7 and R 8 along with the atoms to which they are attached, are joined to form substituted or unsubstituted cyclopropyl and substituted or unsubstituted tetrahydrofuran.
• R 9 and R 9a are each members independently selected from H, 2-hydroxyethyl, methyl, (S)-methyl, (R)-methyl, halogen, cyano, hydroxyl, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or unsubstituted pyrazolyl.
• R 6 is a member selected from
• R 8 , R 8a , R 9 and R 9a are each H.
• R 6 is a member selected from
• R 7 and R 7a are each independently selected from H, methyl and hydroxy.
• R 6 is a member selected from
• R 7 is a member selected from hydroxy, methyl, ethyl and hydroxymethyl
• C* is in a configuration which is a member selected from R and S.
• R 8 is a member selected from hydroxy, methyl, ethyl and hydroxymethyl
• C** is in a configuration which is a member selected from R and S.
• R 7 and R 8 , along with C* and C**, are joined to form a member selected from substituted or unsubstituted cyclopropyl, substituted or unsubstituted tetrahydrofuran and substituted or unsubstituted cyclopentyl and wherein C* and C** are each independently in a configuration which is a member selected from R and S.
• R 6 is a member selected from
• R 7 and R 7a are joined with C* to form a carbonyl; and R 8 is methyl.
• v is 1 and R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted methyl, substituted or unsubstituted methoxy, substituted or unsubstituted methylthio, substituted or unsubstituted ethoxy, substituted or unsubstituted isopropyloxy, cyclopropyl, pyrazol-1-yl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl.
• v is 1 and R 10 is a member selected from fluoro, chloro, cyano, hydroxyl, methyl, trifluoromethyl, methoxy, trifluoromethoxy, difluoromethoxy, isopropyloxy, cyclopropyl, ethoxy, pyrazol-1-yl, phenyl, chlorophenyl and chlorobenzyl.
• v is 1.
• R 6 is ⁇ t ⁇ and R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted methyl, substituted or unsubstituted methoxy, substituted or unsubstituted methylthio, substituted or unsubstituted ethoxy, substituted or unsubstituted isopropyloxy, cyclopropyl, t-butyl, pyrazol-1-yl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl.
• R 6 is and R 10 is a member selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro. In an exemplary embodiment, R 6 is a member selected from
• R is a member selected from
• R , 10 is a member selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro
• R , 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C 3 -Cs cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or unsubstituted pyrazolyl.
• halogen cyano, hydroxyl, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C 3 -Cs cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or unsubstituted pyr
• R is a member selected from and
• R , 10 is a member selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• R 5 is H
• R 6 is a member selected from
• R 10 is a member selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• R 5 is H
• R 6 is a member selected from (4-trifluoromethyl)benzyl, (3-trifluoromethyl)benzyl, (2- trifluoromethyl)benzyl, (4-trifluoromethoxy)benzyl, (3 -trifluoromethoxy )benzyl, (2- trifluoromethoxy)benzyl, (4-fluoro)benzyl, (4-chloro) benzyl, (3-fluoro)benzyl, (3- chloro)benzyl, (2-fluoro)benzyl, (2-chloro)benzyl, (4-methyl)benzyl, (3-methyl)benzyl, (2- methyl)benzyl, (4-t-butyl)benzyl, (4-phenyl)benzyl, (3-phenyl)benzyl, (2-phenyl)benzyl, (2-phenyl)
• R 6 is
• R 6 is a member selected
• R 10 is a member selected from
• R 5 is H
• R 6 is a member independently selected from halogen, cyano, hydroxyl, substituted or unsubstituted methyl, substituted or unsubstituted methoxy, substituted or unsubstituted methylthio, substituted or unsubstituted ethoxy, substituted or unsubstituted isopropyloxy, cyclopropyl, t-butyl, pyrazol-1-yl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl.
• R 5 is H
• R 6 is a member independently selected from halogen, cyano, hydroxyl, substituted or unsubstituted methyl, substituted or unsubstituted methoxy, substituted or unsubstituted methylthio, substituted or unsubstituted ethoxy, substituted or unsubstituted isopropyloxy, cyclopropyl, t
• each R 10 is a member independently selected from halogen, cyano, hydroxyl, substituted or unsubstituted methyl, substituted or unsubstituted methoxy, substituted or unsubstituted methylthio, substituted or unsubstituted ethoxy, substituted or unsubstituted isopropyloxy, cyclopropyl, t-butyl, pyrazol-1-yl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl.
• R 6 is s wherein each R 10 is a member independently selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• each R 10 is a member independently selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• R 5 is H and R 6 is a member selected from
• R 10 wherein each R is a member independently selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• R is , wherein R 10 * is a member selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro, R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted C 1 -C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or unsubstituted pyrazolyl.
• R 10 * is a member selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro
• R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted
• R 5 is H
• R 6 is R 10
• R 10 * is a member selected from cyclopropyl, trifluoromethoxy, trifluoromethyl, chloro and fluoro
• R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted C 1 -C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or unsubstituted pyrazolyl.
• R is , wherein R 10 * is a member selected from chloro and fluoro, and R , 10 is a member selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• R 6 is R1 ° wherein R 10 * is a member selected from cyclopropyl, trifluoromethoxy, trifluoromethyl, chloro and fluoro, and R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy and trifluoromethylthio.
• R 10 * is a member selected from cyclopropyl, trifluoromethoxy, trifluoromethyl, chloro and fluoro
• R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubsti
• R 5 is H
• R 6 is wherein R 10 * is a member selected from chloro and fluoro
• R , 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted Ci-C 4 alkyl, substituted or unsubstituted C 3 -Cs cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or unsubstituted pyrazolyl.
• R 0 is R1 ° wherein R 10 * is a member selected from substituted or unsubstituted C1-C4 alkoxy and substituted or unsubstituted Ci-C 4 alkyl, and R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted Ci-C 4 alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or
• R 5 is H and R 6 is R1 ° wherein R 10 * is a member selected from substituted or unsubstituted Ci-C 6 alkoxy and substituted or unsubstituted Ci-C 4 alkyl, and R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted Ci-C 4 alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or unsubstituted pyrazolyl.
• R 10 * is a member selected from substituted or unsubstituted Ci-C 6 alkoxy and substituted or unsubstituted Ci-C 4 alkyl
• R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted Ci-C 4 alky
• R 5 is H and R 6 is wherein R 10 * is a member selected from methyl and methoxy, and R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted Ci-C 4 alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubstituted phenyloxy, trifluoromethylthio and substituted or unsubstituted pyrazolyl.
• R 5 is H and R 6 is wherein R 10 * is a member selected from methyl and methoxy, and R 10 is a member selected from halogen, cyano, hydroxyl, substituted or unsubstituted Ci-C 4 alkyl, substituted or unsubstituted C 3 -Cg cycloalkyl, substituted or unsubstituted Ci-C 4 alkyloxy, substituted or unsubsti
• R 10 * is a member selected from methyl and methoxy
• R 10 is a member selected from chloro, fluoro, trifluoromethyl and trifluoromethoxy.
• R 6 is a member selected from 2,3-dichlorobenzyl, 2,3 dimethylbenzyl, 2-methyl-3-chlorobenzyl, 2-trifluoromethyl-4-fluorobenzyl, 2-trifluoromethyl- 4-chlorobenzyl, 4-trifluoromethyl-2-fluorobenzyl, 4-trifluoromethoxy-2-methoxybenzyl, 2- fluoro-4-chlorobenzyl, 2-chloro-4-fluorobenzyl, 2,4-difluorobenzyl, 2-methyl-4-chlorobenzyl, 2-fluoro-4-methylbenzyl, 2-methyl-5-fluorobenzyl, 2-methyl-5-chlorobenzyl, 2,5- dichlorobenzyl, 2,5-difluorobenzyl, 2-fluoro-5-trifluoromethyl benzyl, 2-trifluoromethyl-5- fluorobenzyl, 2-chloro-6-fluoro benz
• R 5 is H
• R 6 is a member selected from 2,3-dichlorobenzyl, 2,3 dimethylbenzyl, 2-methyl-3-chlorobenzyl, 2-trifluoromethyl-4-fluorobenzyl, 2-trifluoromethyl- 4-chlorobenzyl, 4-trifluoromethyl-2-fluorobenzyl, 4-trifluoromethoxy-2-methoxybenzyl, 2- fluoro-4-chlorobenzyl, 2-chloro-4-fluorobenzyl, 2,4-difluorobenzyl, 2-methyl-4-chlorobenzyl, 2-fluoro-4-methylbenzyl, 2-methyl-5-fluorobenzyl, 2-methyl-5-chlorobenzyl, 2,5- dichlorobenzyl, 2,5-difluorobenzyl, 2-fluoro-5-trifluoromethyl benzyl, 2-trifluoromethyl-5- fluorobenzyl, 2-chloro-6-fluoro
• R 6 is a member selected from 2-chloro-4- trifluoromethylbenzyl, 2-methoxy-4-trifluoromethoxybenzyl, (l-(4- chlorophenyl)cyclopropyl)methyl, 2-methyl-3 -chlorobenzyl, 2-fluoro-3-trifluoromethylbenzyl, l-(4-trifluoromethylbenzyl)ethyl, 2,5-dichlorobenzyl and 2-fluoromethoxy-2-methyl-propyl. [0100] In an exemplary embodiment, R 6 is a member selected from 2-chloro-4- trifluoromethylbenzyl, 2-methoxy-4-trifluoromethoxybenzyl, (l-(4- chlorophenyl)cyclopropyl)methyl, 2-methyl-3 -chlorobenzyl, 2-fluoro-3-trifluoromethylbenzyl, l-(4-trifluoromethylbenzyl)ethyl, 2,5-dichloro
• R 6 is
• each R 10 is a member independently selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• R is a member selected from
• R is a member selected from
• each R 10 is a member independently selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• R 5 is H
• R 6 is a member selected from
• each R 10 is a member independently selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• R 6 is a member selected from 2,3,5-trifluorobenzyl, 3,4,5-trifluorobenzyl and 2,3,6-trifluorobenzyl.
• R 5 is H and R 6 is a member selected from 2,3,5-trifluorobenzyl, 3,4,5-trifluorobenzyl and 2,3,6-trifluorobenzyl.
• R 6 is a member selected from
• R 6 is a member selected from 2-(halophenoxy)ethyl, 2- (halophenoxy)propyl, 2-(phenoxy)ethyl, 2-(phenoxy)propyl, 2-((Ci-C 4 )alkylphenoxy)ethyl, 2- ((Ci-C4)alkylphenoxy)propyl.
• R 6 is a member selected from 2- (fluorophenoxy)ethyl, 2-(chlorophenoxy)ethyl, 2-(fluorophenoxy)propyl, 2- (chlorophenoxy)propyl, 2-(phenoxy)ethyl, 2-(phenoxy)propyl, 2-(ethylphenoxy)ethyl, 2- (ethylphenoxy)propyl, 2-(methylphenoxy)ethyl, 2-(methylphenoxy)propyl.
• R 6 is a member selected from 2-(2-fluorophenoxy)ethyl, 2-(2- chlorophenoxy)ethyl, 2-(2-fluorophenoxy)propyl, 2-(2-chlorophenoxy)propyl, 2-(3- fluorophenoxy)ethyl, 2-(3-chlorophenoxy)ethyl, 2-(3-fluorophenoxy)propyl, 2-(3- chlorophenoxy)propyl, 2-(4-fluorophenoxy)ethyl, 2-(4-chlorophenoxy)ethyl, 2-(4- fluorophenoxy)propyl, 2-(4-chlorophenoxy)propyl.
• R 6 is a member selected from 2-(4-methylphenoxy)ethyl, 2-(4-methylphenoxy)propyl, 2-(3- methylphenoxy)ethyl, 2-(3-methylphenoxy)propyl, 2-(2-methylphenoxy)ethyl, 2-(2- methylphenoxy)propyl.
• R 6 is a member selected from 2-(3- chlorophenoxy)ethyl, 2-(2-chlorophenoxy)propyl, 2-(2-chlorophenoxy)ethyl, 2-(4- methylphenoxy)ethyl, 2-phenoxypropyl, 2-(2-fluorophenoxy)ethyl, 2-phenoxyethyl, 2-(4- chlorophenoxy)ethyl and 2-(4-fluorophenoxy)-2-methylpropyl. [0102] In an exemplary embodiment, R 6 is a member selected from 2-(3- chlorophenoxy)ethyl, 2-(2-chlorophenoxy)propyl, 2-(2-chlorophenoxy)ethyl, 2-(4- methylphenoxy)ethyl, 2-phenoxypropyl, 2-(2-fluorophenoxy)ethyl, 2-phenoxyethyl, 2-(4- chlorophenoxy)ethyl and 2-(4-fluorophenoxy)-2-methylpropy
• R 6 is 2-[(halophenyl)amino]ethyl. In an exemplary embodiment, R 6 is a member selected from 2-[(chlorophenyl)amino]ethyl and 2-[(fluorophenyl)amino]ethyl. In an exemplary embodiment, R 6 is a member selected from 2-[(4-halophenyl)amino]ethyl, 2- [(3-halophenyl)amino]ethyl and 2-[(2-halophenyl)amino]ethyl. In an exemplary embodiment, R 6 is 2-[(4-chlorophenyl)amino]ethyl.
• R 6 is H 2 .
• R 6 is a member selected from 1 -(substituted or unsubstituted phenyl)ethyl and 2- methyl-2-halophenoxypropyl.
• R 6 is a member selected from 1- (4-trifluorophenyl)ethyl and 2-methyl-2-(4-fluorophenoxy)propyl.
• R 6 is a member selected from
• R 1Oa is a member selected from H, substituted or unsubstituted (Ci-Cio)alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl and substituted or unsubstituted heteroaryl.
• R 1Oa is a member selected from H, (Ci- C 4 )alkyl, phenyl and halobenzyl.
• R 1Oa is a member selected from methyl, phenyl and 4-chlorobenzyl.
• w is 1, R 10 is a member selected from substituted or unsubstituted (Ci-C4)alkyl, substituted or unsubstituted phenyl and substituted or unsubstituted benzyl, and R 1Oa is a member selected from (Ci-C4)alkyl, substituted or unsubstituted phenyl and substituted or unsubstituted benzyl.
• w is 1, R 10 is a member selected from (Ci-C 4 )alkyl and halobenzyl, and R 1Oa is a member selected from (Ci-C 4 )alkyl, phenyl and halobenzyl.
• w is 1, R 10 is a member selected from methyl and chlorobenzyl, and R 1Oa is a member selected from methyl, phenyl and chlorobenzyl.
• w is 1, R 10 is a member selected from methyl and 4-chlorobenzyl, and R 1Oa is a member selected from methyl, phenyl and 4-chlorobenzyl.
• R 6 is a member selected from
• R is
• R 6 is
• R 6 isr a mem>ber selected from
• R is substituted or unsubstituted pyridin-2-yl.
• R 6 is a member selected from (Ci-C 4 )alkylpyridin-2-yl and di(Ci-C 4 )alkylpyridin-2-yl.
• R 6 is a member selected from 4-(Ci-C 4 )alkylpyridin-2-yl, 3-(Ci-C 4 )alkyl-5-(Ci-C 4 )alkylpyridin-2-yl and 3-(Ci-C 4 )alkyl-6- (Ci-C 4 )alkylpyridin-2-yl.
• R 6 is a member selected from 4- methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl and 3-ethyl-6-methylpyridin-2-yl.
• R 6 is substituted or unsubstituted pyridin-3-yl.
• R 6 is a member selected from pyridin-3-yl, (C 1 - C4)alkoxypyridin-3-yl, (substituted or unsubstituted(Ci-C4)alkyl)pyridin-3-yl and di(Ci- C 4 )alkylpyridin-3-yl.
• R 6 is a member selected from 5,6- dimethylpyridin-3-yl and 6-methoxypyridin-3-yl.
• R 6 is a member selected from 6-halopyridin-3- ylmethyl and (6-halomethyl)pyridin-3-ylmethyl. In another exemplary embodiment, R 6 is a member selected from 6-chloropyridin-3-ylmethyl and 6-(trifluoromethyl)pyridin-3-ylmethyl.
• R 6 is a member selected from 1,7 naphthylpyridine, isoquinolinyl and 6,7 dihydrocyclopentapyridinyl. In another exemplary embodiment, R 6 is a member selected from
• R is a member selected from 1,7 naphthylpyridine, isoquinolinyl and 6,7 dihydrocyclopentapyridinyl.
• R 5 is methyl and R 6 is 2,3-dihydro-l-benzofuran- 2-ylmethyl.
• R 6 is substituted or unsubstituted pyridin-3-yl.
• R 6 is a member selected from pyridin-3-yl, (Ci- C4)alkoxypyridin-3-yl, (substituted or unsubstituted(Ci-C4)alkyl)pyridin-3-yl and di(Ci- C 4 )alkylpyridin-3-yl.
• R 6 is a member selected from 5,6- dimethylpyridin-3-yl and 6-methoxypyridin-3-yl.
• B is a member selected from substituted or unsubstituted 6-membered aryl and substituted or unsubstituted 6-membered heteroaryl.
• B is a member selected from 6-membered aryl, halo 6- membered aryl, cyano 6-membered aryl, (C 1 -C 4 alkyl) 6-membered aryl, (C 1 -C 4 haloalkyl) 6- membered aryl, (C1-C4 alkoxy) 6-membered aryl, (C1-C4 haloalkoxy) 6-membered aryl.
• B is a member selected from 6-membered heteroaryl, halo 6- membered heteroaryl, cyano 6-membered heteroaryl, (C1-C4 alkyl) 6-membered heteroaryl, (C 1 -C 4 haloalkyl) 6-membered heteroaryl, (C 1 -C 4 alkoxy) 6-membered heteroaryl, (C 1 -C 4 haloalkoxy) 6-membered heteroaryl. [0115] In an exemplary embodiment, B has a formula which is a member selected from
• R 15 is a member selected from halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, halo(Ci-C 4 )alkoxy.
• B is a member selected from
• B is a member selected from
• B is a member selected from
• B is a member selected from
• R , D 15 is a member selected from fluoro, chloro and cyano.
• B is a member selected from
• B is a member selected from
• B is a member selected from
• B is
• B is In an exemplary embodiment,
• B is
• Z is a member selected from substituted or unsubstituted thiazolyl, substituted or unsubstituted thiadiazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted tetrazolyl, substituted or unsubstituted triazolyl and substituted or unsubstituted pyrazolyl.
• Z is substituted or unsubstituted thiazolyl.
• Z is substituted or unsubstituted thiadiazolyl.
• Z is a member selected from substituted or unsubstituted thiazol-2-yl, substituted or unsubstituted thiazol-4-yl, substituted or unsubstituted thiazol-5-yl, substituted or unsubstituted thiadiazol-2-yl, substituted or unsubstituted thiadiazol- 5-yl, substituted or unsubstituted pyrazol-3-yl, substituted or unsubstituted pyrazol-4-yl, substituted or unsubstituted pyrazol-5-yl, substituted or unsubstituted isoxazol-5-yl, substituted or unsubstituted isoxazol-4-yl, substituted or unsubstituted isoxazol-3-yl, substituted or unsubstituted tetrazol-5-yl, substituted or unsubstituted triazol-3-yl and substituted or unsubfluor unsubsti
• Z is a member selected from substituted or unsubstituted 1,3 thiazolyl, substituted or unsubstituted 1,2,4 thiadiazolyl, substituted or unsubstituted 1 ,3 ,4 thiadiazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted 2H-tetrazolyl, substituted or unsubstituted 2H- 1,2,3 triazolyl, substituted or unsubstituted 2H- 1,2,4 triazolyl and substituted or unsubstituted lH-pyrazolyl.
• Z is a member selected from substituted or unsubstituted 1 ,3 thiazol-2-yl, substituted or unsubstituted 1 ,3 thiazol-4-yl, substituted or unsubstituted 1 ,3 thiazol-5-yl, substituted or unsubstituted 1,3,4 thiadiazol-2-yl, substituted or unsubstituted 1,2,4 thiadiazol-5-yl, substituted or unsubstituted lH-pyrazol-3-yl, substituted or unsubstituted IH- pyrazol-4-yl, substituted or unsubstituted lH-pyrazol-5-yl, substituted or unsubstituted isoxazol-5-yl, substituted or unsubstituted isoxazol-4-yl, substituted or unsubstituted isoxazol- 3-yl, substituted or unsubstituted 2H-te
• Z is a member selected from 1,3 thiazol-2-yl, (halo) 1,3 thiazol-2-yl, (substituted or unsubstitued (Ci-Cio)alkyl)l,3 thiazol-2-yl, 1,3 thiazol-4-yl, (substituted or unsubstitued (Ci-Cio)alkyl)l,3 thiazol-4-yl, 1,3 thiazol-5-yl, (substituted or unsubstitued (Ci-Cio)alkyl)l,3 thiazol-5-yl, (substituted or unsubstitued (Ci-Cio)alkyl) 1,3,4 thiadiazol-2-yl, 1,3,4 thiadiazol-2-yl, (substituted or unsubstitued (Ci-Cio)alkyl) 1,2,4
• Z is a member selected from 1,3 thiazol-2-yl, (halo)l,3 thiazol-2-yl, (substituted or unsubstitued (Ci-C 4 )alkyl)l,3 thiazol-2-yl, 1,3 thiazol-4- yl, (substituted or unsubstitued (Ci-C4)alkyl)l,3 thiazol-4-yl, 1,3 thiazol-5-yl, (substituted or unsubstitued (Ci-C4)alkyl)l,3 thiazol-5-yl, (substituted or unsubstitued (Ci-C4)alkyl) 1,3,4 thiadiazol-2-yl, 1,3,4 thiadiazol-2-yl, (substituted or unsubstitued (Ci -C 4 )alkyl) 1,2,4 thiadiazol
• Z is a member selected from 1,3 thiazol-2-yl, (5-chloro) 1 ,3 thiazol-2-yl, (4-methyl) 1 ,3 thiazol-2-yl, (5-methyl) 1 ,3 thiazol-2-yl, 4(methoxycarbonyl)(l,3 thiazol-2-yl), 4-trifluoromethyl 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 2- methyl 1,3 thiazol-4-yl, 1,3 thiazol-5-yl, 2-methyl 1,3 thiazol-5-yl, 4-trifluoromethyl 1,3,4 thiadiazol-2-yl, 5-methyl 1,3,4 thiadiazol-2-yl, 1,3,4 thiadiazol-2-yl, 3-methyl 1,2,4 thiadiazol- 5-yl, 3-ethyl 1,2,4 thiadiazol-5-yl, 1,2,4 thiadiazol-5-yl, 1-methyl
• Z is a member selected from 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl), 4-methyl(l,3 thiazol-2-yl), 5-methyl(l,3 thiazol-2- yl), 4(methoxycarbonyl)(l,3 thiazol-2-yl), 4-trifluoromethyl 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 2-methyl 1,3 thiazol-4-yl, 3-methyl 1,2,4 thiadiazol-5-yl, 3-ethyl 1,2,4 thiadiazol-5-yl, unsubstituted 1,2,4 thiadiazol-5-yl.
• Z is a member selected from 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5-yl.
• Z is a member selected from 1,3 thiazol-2-yl, 1 ,3 thiazol-4-yl, 5-chloro(l ,3 thiazol-2-yl), 5-methyl(l ,3 thiazol-2-yl) and 1 ,2,4 thiadiazol-5-yl.
• Z is a member selected from 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5-yl.
• Z is 1,3 thiazol-2-yl.
• Z is 5-chloro(l,3 thiazol-2-yl).
• Z is 1,2,4 thiadiazol-5-yl.
• B is * and Z is a member selected from substituted or unsubstituted thiazolyl, substituted or unsubstituted thiadiazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted tetrazolyl, substituted or unsubstituted triazolyl and substituted or unsubstituted pyrazolyl.
• B is
• * and Z is a member selected from 1,3 thiazol-2-yl, (halo) 1,3 thiazol-2-yl,
• B is * and Z is 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5-yl.
• Z is 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5-yl.
• B is * and Z is 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5- halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5-yl.
• R 5 is H
• R 6 is a member selected from 3-chlorobenzyl, 3-fluorobenzyl, 3-trifluoromethylbenzyl, 3-trifluoromethoxybenzyl, 4-chlorobenzyl, 4- fluorobenzyl, 4-trifluoromethylbenzyl, 4-trifluoromethoxybenzyl, 3-chloro-4- trifluoromethoxybenzyl, 3 -chloro-4-trifluoromethylbenzyl, 3 -fluoro-4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3,4 dichlorobenzyl, 2,5 dichlorobenzyl, 3-chloro-4- fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3-fluoro-4-chlorobenzyl, 2-fluoro-4- trifluoromethylbenzyl, 3-cyclopropyl-4-fluorobenzyl, 2-me
• s represents a bond covalently attached to said carbon of said carbonyl, and s represents a bond covalently attached to said sulfur of said sulfonamide.
• R 5 is H
• R 6 is a member selected from 1 -(substituted or unsubstituted phenyl)ethyl and 2-methyl-2-halophenoxypropyl
• B is a member selected from
• ' represents a bond covalently attached to said sulfur of said sulfonamide.
• R 5 is H
• R 6 is a member selected from l-(4- trifluorophenyl)ethyl, 2-methyl-2-(4-fluorophenoxy)propyl, 2-chloro-4-trifluoromethylbenzyl, 2-methoxy-4-trifluoromethoxybenzyl, ( 1 -(4-chlorophenyl)cyclopropyl)methyl, 2-methyl-3 - chlorobenzyl, 2-fluoro-3-trifluoromethylbenzyl, l-(4-trifluoromethylbenzyl)ethyl, 2,5- dichlorobenzyl and 2-fluoromethoxy-2-methyl-propyl; and B is a member selected from
• ⁇ s represents a bond covalently attached to said carbon of said carbonyl, and s represents a bond covalently attached to said sulfur of said sulfonamide.
• R 5 is H
• R 6 is a member selected from 3-chlorobenzyl, 3-fluorobenzyl, 3-trifluoromethylbenzyl, 3-trifluoromethoxybenzyl, 4-chlorobenzyl, 4- fluorobenzyl, 4-trifluoromethylbenzyl, 4-trifluoromethoxybenzyl, 3-chloro-4- trifluoromethoxybenzyl, 3 -chloro-4-trifluoromethylbenzyl, 3 -fluoro-4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3,4 dichlorobenzyl, 2,5 dichlorobenzyl, 3-chloro-4- fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3-fluoro-4-chlorobenzyl, 2-fluoro-4- trifluoromethylbenzyl, 3-cyclopropyl-4-fluorobenzyl, 2-me
• R 5 is H
• R 6 is a member selected from 1 -(substituted or unsubstituted phenyl)ethyl and 2-methyl-2-halophenoxypropyl
• Z is a member selected from 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5-yl.
• R 5 is H
• R 6 is a member selected from l-(4- trifluorophenyl)ethyl, 2-methyl-2-(4-fluorophenoxy)propyl, 2-chloro-4-trifluoromethylbenzyl, 2-methoxy-4-trifluoromethoxybenzyl, ( 1 -(4-chlorophenyl)cyclopropyl)methyl, 2-methyl-3 - chlorobenzyl, 2-fluoro-3-trifluoromethylbenzyl, l-(4-trifluoromethylbenzyl)ethyl, 2,5- dichlorobenzyl and 2-fluoromethoxy-2-methyl-propyl; and Z is a member selected from 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5-
• s represents a bond covalently attached to said carbon of said carbonyl; s represents a bond covalently attached to said sulfur of said sulfonamide; and Z is a member selected from 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2- yl) and 1,2,4 thiadiazol-5-yl.
• R 5 is H;
• R 6 is a member selected from 3-chlorobenzyl, 3-fluorobenzyl, 3-trifluoromethylbenzyl, 3-trifluoromethoxybenzyl, 4-chlorobenzyl, 4- fluorobenzyl, 4-trifluoromethylbenzyl, 4-trifluoromethoxybenzyl, 3-chloro-4- trifluoromethoxybenzyl, 3 -chloro-4-trifluoromethylbenzyl, 3 -fluoro-4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3,4 dichlorobenzyl, 2,5 dichlorobenzyl, 3-chloro-4- fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3-fluoro-4-chlorobenzyl, 2-fluoro-4- trifluoromethylbenzyl, 3-cyclopropyl-4-fluorobenzyl, 2-me
• i .n i s represents a bond covalently attached to said carbon of said carbonyl; s represents a bond covalently attached to said sulfur of said sulfonamide; Z is a member selected from 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2- yl) and 1,2,4 thiadiazol-5-yl.
• R 5 is H
• R 6 is a member selected from 1 -(substituted or unsubstituted phenyl)ethyl and 2-methyl-2-halophenoxypropyl
• B is a member selected from
• s represents a bond covalently attached to said carbon of said carbonyl; s represents a bond covalently attached to said sulfur of said sulfonamide; Z is a member selected from 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2- yl) and 1,2,4 thiadiazol-5-yl.
• R 5 is H
• R 6 is a member selected from l-(4- trifluorophenyl)ethyl, 2-methyl-2-(4-fluorophenoxy)propyl, 2-chloro-4-trifluoromethylbenzyl, 2-methoxy-4-trifluoromethoxybenzyl, ( 1 -(4-chlorophenyl)cyclopropyl)methyl, 2-methyl-3 - chlorobenzyl, 2-fluoro-3-trifluoromethylbenzyl, l-(4-trifluoromethylbenzyl)ethyl, 2,5- dichlorobenzyl and 2-fluoromethoxy-2-methyl-propyl; and Z is a member selected from 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5-
• Z is a member selected from 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-alkyl(l,3 thiazol-2- yl) and 1,2,4 thiadiazol-5-yl.
• B is
• Z is a member selected from 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5- yl;
• R 5 is H
• R 6 is a member selected from 3-chloro-4-trifluoromethoxybenzyl, 3-chloro-4- trifluoromethylbenzyl, 3-fluoro-4-trifluoromethoxybenzyl, 3,4 dichlorobenzyl, 3-fluoro-4- trifluoromethylbenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 4-trifluoromethoxybenzyl, 4- trifluoromethylbenzyl, 3-fluoro-4-chlorobenzyl, 3-chloro-4-fluorobenzyl, 3-trifluoromethoxy- 4-fluorobenzyl, 3-cyclopropyl-4-fluorobenzyl, 2-methoxy-4-trifluoromethoxybenzyl, 3,4- difluorobenz
• Z is 1,3 thiazol-2-yl; R 5 is H; R 6 is a member selected from 3-chloro-4-trifluoromethylbenzyl, 3 -fluoro-4-trifluoromethoxybenzyl, 3 -fluoro-4-trifluoromethylbenzyl, 3 -trifluoromethoxy-4- fluorobenzyl, 3-cyclopropyl-4-fluorobenzyl, 3-trifluoromethyl-4-fluorobenzyl, 2-methoxy-4- trifluoromethoxybenzyl, 2-methyl-3-chlorobenzyl, 3-trifluoromethoxybenzyl, 3-fluoro-4- trifluoromethylbenzyl, 2-fluoro-3-trifluoromethylbenzyl and 3-trifluoromethylbenzyl.
• B is
• Z is 5-chloro(l,3 thiazol-2-yl); R 5 is H; R 6 is a member selected from 3,4 dichlorobenzyl, 3- fluoro-4-trifluoromethoxybenzyl, 3-chloro-4-fluorobenzyl, 3 -fluoro-4-trifluoromethylbenzyl, 3- trifluoromethoxy-4-fluorobenzyl, 4-trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-fluoro- 4-chlorobenzyl, 3-trifluoromethyl-4-fluorobenzyl, 2-fluoro-3-trifluoromethylbenzyl, 3,4- difluorobenzyl, 3-trifluoromethoxybenzyl and 3-trifluoromethylbenzyl.
• B is
• Z is 1,2,4 thiadiazol-5-yl; R 5 is H; R 6 is a member selected from 3-chloro-4- trifluoromethoxybenzyl, 3 -chloro-4-trifluoromethylbenzyl, 3 -fluoro-4-trifluoromethoxybenzyl, 3 -fluoro-4-trifluoromethylbenzyl and 4-trifluoromethylbenzyl.
• B is
• Z is (1,3 thiazol-4-yl).
• B is
• Z is (1,3 thiazol-4-yl); R 5 is H; and R 6 is a member selected from 3,4 dichlorobenzyl, 3-fluoro- 4-trifluoromethoxybenzyl, 3-chloro-4-fluorobenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3- trifluoromethoxy-4-fluorobenzyl, 4-trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-fluoro- 4-chlorobenzyl, 3-trifluoromethyl-4-fluorobenzyl, 2-fluoro-3-trifluoromethylbenzyl, 3,4- difluorobenzyl, 3-trifluoromethoxybenzyl and 3-trifluoromethylbenzyl.
• Z is (1,3 thiazol-4-yl), R 5 is H and R 6 is A- trifluoromethylbenzyl.
• B is
• R , 5 is H, R is 4-trifluoromethylbenzyl.
• B is
• Z is (1,3 thiazol-4-yl), R 5 is H, R 6 is 4-trifluoromethylbenzyl.
• B is
• Z is a member selected from 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5- yl;
• R 5 is H; and
• R 6 is a member selected from 3-chloro-4-trifluoromethoxybenzyl, 3-chloro-4- trifluoromethylbenzyl, 3 -fluoro-4-trifluoromethylbenzyl, 3 -fluoro-4-trifluoromethoxybenzyl, 3,4 dichlorobenzyl, 4-trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-chloro-4- fluorobenzyl, 3-fluoro-4-chlorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3,4-difluorobenzyl, 3-trifluoromethyl-4-fluorobenzyl, 3-trifluoromethoxybenzyl and 3-trifluoromethylbenzyl.
• Z is 1,3 thiazol-2-yl; R is H; R is a member selected from 3-chloro-4-trifluoromethylbenzyl, 3,4 dichlorobenzyl, 3-fluoro-4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3- chloro-4-fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3,4-difluorobenzyl, 4- trifluoromethoxybenzyl, 3-trifluoromethoxybenzyl, 3-fluoro-4-chlorobenzyl and 3- trifluoromethylbenzyl.
• B is
• Z is 5-chloro(l,3 thiazol-2-yl); R is H; R is a member selected from 3-fluoro-4- trifluoromethylbenzyl, 3,4 dichlorobenzyl, 4-trifluoromethoxybenzyl, 3-fluoro-4- trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-fluoro-4-chlorobenzyl, 3,4-difluorobenzyl, 3-trifluoromethyl-4-fluorobenzyl and 3-fluoro-4-trifluoromethoxybenzyl.
• B is
• Z is 1,2,4 thiadiazol-5-yl; R is H; R is a member selected from 3-chloro-4- trifluoromethoxybenzyl, 3 -chloro-4-trifluoromethylbenzyl, 3 -fluoro-4-trifluoromethylbenzyl and 3-fluoro-4-trifluoromethoxybenzyl.
• B is
• Z is a member selected from 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5- yl;
• R 5 is H;
• R 6 is a member selected from 3,4 dichlorobenzyl, 3-fluoro-4- trifluoromethoxybenzyl, 3-chloro-4-fluorobenzyl, 4-trifluoromethoxybenzyl, 3-fluoro-4- chlorobenzyl, 4-trifluoromethylbenzyl, 3-trifluoromethoxybenzyl, 3-trifluoromethylbenzyl, 3- fluoro-4-trifluoromethylbenzyl, 3-trifluoromethyl-4-fluorobenzyl, 3,4-difluorobenzyl and 3- trifluoromethoxy-4-fluorobenzyl.
• B is
• Z is 1,3 thiazol-2-yl; R 5 is H; R 6 is a member selected from 3,4 dichlorobenzyl, 3-fluoro-4- trifluoromethoxybenzyl, 4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3- trifluoromethyl-4-fluorobenzyl, 3-trifluoromethylbenzyl, 3-fluoro-4-chlorobenzyl, 3,4- difluorobenzyl, 3-chloro-4-fluorobenzyl and 4-trifluoromethylbenzyl.
• B is
• Z is 5-chloro(l,3 thiazol-2-yl); R 5 is H; R 6 is a member selected from 3,4 dichlorobenzyl, 3- chloro-4-fluorobenzyl, 3-fluoro-4-chlorobenzyl, 4-trifluoromethoxybenzyl, 3-fluoro-4- trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-trifluoromethoxybenzyl, 3- trifluoromethylbenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3-trifluoromethyl-4-fluorobenzyl, 3,4- difluorobenzyl and 3-trifluoromethoxy-4-fluorobenzyl.
• B is
• Z is a member selected from 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5- yl;
• R 5 is H;
• R 6 is a member selected from 3-chloro-4-trifluoromethylbenzyl, 3-fluoro-4- trifluoromethylbenzyl, 3-fluoro-4-trifluoromethoxybenzyl and 4-trifluoromethylbenzyl.
• B is
• Z is 1,3 thiazol-2-yl; R 5 is H; R 6 is a member selected from 3-chloro-4-trifluoromethylbenzyl, 3-fluoro-4-trifluoromethylbenzyl and 3-fluoro-4-trifluoromethoxybenzyl.
• B is
• Z is 5-chloro(l,3 thiazol-2-yl); R 5 is H; R 6 is a member selected from 3-chloro-4- trifluoromethylbenzyl and 3-fluoro-4-trifluoromethylbenzyl.
• B is
• Z is a member selected from 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5- yl;
• R 5 is H;
• R 6 is a member selected from 3-fluoro-4-trifluoromethoxybenzyl, 4- trifluoromethylbenzyl, 3-chloro-4-trifluoromethylbenzyl and 3,4 dichlorobenzyl.
• B is
• Z is 1,3 thiazol-2-yl; R 5 is H; R 6 is a member selected from 3-fluoro-4-trifluoromethoxybenzyl and 4-trifluoromethylbenzyl.
• B is
• Z is 5-chloro(l,3 thiazol-2-yl); R > 5 i • s T H T ;. r R> 6 is 3,4 dichlorobenzyl.
• B is
• Z is a member selected from 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) and 1,2,4 thiadiazol-5- yl;
• R 5 is H;
• R 6 is a member selected from 3-fluoro-4-trifluoromethoxybenzyl, 3-chloro-4- trifluoromethylbenzyl and 3-fluoro-4-trifluoromethylbenzyl.
• B is
• Z is 5-chloro(l,3 thiazol-2-yl), R is 3-fluoro-4-trifluoromethoxybenzyl.
• B is
• Z is 1,2,4 thiadiazol-5-yl; R 5 is H; R 6 is a member selected from 3-chloro-4- trifluoromethoxybenzyl, 3-chloro-4-trifluoromethylbenzyl and 3-fluoro-4- trifluoromethylbenzyl.
• the invention is a compound of formula (I):
• R 5 and R 6 are each members independently selected from H and a group which is a member selected from (C 1 - Cio)alkyl, heteroalkyl, heterocycloalkyl, heterocycloalkyl(Ci-C 2 )alkyl, (C 3 -Cg)cycloalkyl, (C 3 - C 8 )cycloalkyl(Ci-C 2 )alkyl, aryl(Ci-C 3 )alkyl, aryloxy(Ci-C 2 )alkyl, aiylamino(C 1 -C 2 )alkyl, heteroaryl, heteroarylamino(Ci-C 2 )alkyl, heteroaryloxy(Ci-C 2 )alkyl and heteroaryl(Ci- C 2 )alkyl.
• Each group is optionally substituted at any suitable point with one or more substituents selected from the group consisting of oxo, halogen, cyano, hydroxy, (Ci-C4)alkyl, halo(Ci-C 4 )alkyl, (d-C 4 )alkoxy, (Ci-C 4 )alkoxy(Ci-C 4 )alkoxy, hydroxy(Ci-C 4 )alkyl, hydroxy(Ci-C 4 )alkoxy, halo(Ci-C 4 )alkoxy, (C3-C8)cycloalkyl(Ci-C 4 )alkoxy, amino, (Ci- C 4 )alkylamino, di(Ci-C 4 )alkylamino, trifluoromethylthio, (C3-Cg)cycloalkyl, pyrazolyl, pyrazolylmethyl, pyrazolylethyl, phenyl, benzyl, pheneth
• Each pyrazolyl, pyrazolylmethyl, pyrazolylethyl, phenyl, benzyl, phenethyl, pyridyl, pyridylmethyl, phenoxy, phenoxymethyl, pyridyloxy or pyridyloxymethyl is optionally substituted with halogen, cyano, hydroxy, methyl, methoxy, trifluoromethyl or trifluoromethoxy.
• R 5 and R 6 are not both hydrogen.
• R 5 and R 6 when taken together with the nitrogen to which they are attached, are optionally joined to form a 4- to 8- membered heterocycloalkyl ring.
• the 4- to 8- membered heterocycloalkyl ring is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen, cyano, hydroxy, (Ci-C 4 )alkyl, halo(Ci- C 4 )alkyl, (C r C 4 )alkoxy, (Ci-C 4 )alkoxy(Ci-C 4 )alkoxy, hydroxy(d-C 4 )alkoxy, halo(C r C 4 )alkoxy, (C 3 -C 8 )cycloalkyl(Ci-C 4 )alkoxy, (C 3 -C 8 )cycloalkyl(Ci-C 4 )alkoxy(Ci-C 4 )alkyl, amino, (Ci-C 4 )alkylamino, di(Ci-C 4 )alkylamino, trifluoromethylthio, (C3-Cg)cycloalky
• Each pyrazolyl, pyrazolylmethyl, pyrazolylethyl, phenyl, benzyl, phenethyl, pyridyl, pyridylmethyl, phenoxy, phenoxymethyl, pyridyloxy or pyridyloxymethyl is optionally substituted with halogen, cyano, hydroxy, methyl, methoxy, trifluoromethyl or trifluoromethoxy.
• B is a member selected from the group consisting of aryl and 6-membered heteroaryl.
• Each B is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, (Ci-C 4 )alkyl, halo(Ci- C 4 )alkyl, (Ci-C 4 )alkoxy and halo(Ci-C 4 )alkoxy.
• Z is a 5 -membered heteroaryl, which is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxycarbonyl, (Ci-C 4 )alkoxy, halo(Ci-C 4 )alkoxy, (C3-Cg)cycloalkyl, amino, (Ci-C 4 )alkylamino and di(Ci-C 4 )alkylamino.
• substituents selected from the group consisting of halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxycarbonyl, (Ci-C 4 )alkoxy, halo(Ci-C 4 )alkoxy, (C3-Cg)cycloal
• an embodiment described herein has a proviso that the compound of formula (I) is not one of the following compounds: N-(5 -methyl-3 -isoxazolyl)-3- [ [(5 -methyl-3 -isoxazolyl)amino]sulfonyl] -benzamide; 3 -[ [(5 -methyl-3 - isoxazolyl)amino]sulfonyl]-N-l,3,4-thiadiazol-2-yl-benzamide; N-(5-ethyl-l,3,4-thiadiazol-2- yl)-3-(4-morpholinylcarbonyl)-benzenesulfonamide; 1 -[3-[[[5-(1 , 1 -dimethylethyl)-4-methyl-2- thiazolyl]amino]sulfonyl]benzoyl] piperidine; N-(5-methyl-l,3,4-
• R 5 in any of the embodiments of the previous paragraphs, is (Ci-Cio)alkyl or (C 3 -C 8 )cycloalkyl.
• This R 5 can be optionally substituted with one or more substituents such as oxo, halogen, cyano, hydroxy, hydroxy(Ci-C 4 )alkyl, hydroxy(Ci-C 4 )alkoxy, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, halo(Ci-C 4 )alkoxy or phenyl.
• substituents such as oxo, halogen, cyano, hydroxy, hydroxy(Ci-C 4 )alkyl, hydroxy(Ci-C 4 )alkoxy, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy
• R 5 in any of the embodiments of the previous paragraphs, (Ci-C 4 )alkyl, hydroxy(Ci-C 4 )alkyl, cyano(Ci-C 4 )alkyl, (C 3 -Cg)cycloalkyl, phenyl(Ci-C 4 )alkyl, hydroxycyclohexyl or hydroxy(Ci-C 4 )alkylcyclohexyl.
• R 5 in any of the embodiments of the previous paragraphs, is methyl, ethyl, isopropyl, hydroxyethyl, cyanoethyl, 2-hydroxy-l-phenylethyl, cyclopropyl, cyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2R) 2-hydroxycyclohexyl, (IR, 2S) (2-hydroxymethyl)cyclohexyl or (IS, 2R) (2-hydroxymethyl)cyclohexyl.
• R 6 in any of the embodiments of the previous paragraphs is either H or it is not H.
• R 6 in any of the embodiments of the previous paragraphs, is heteroaryl, aryl(Ci-C 3 )alkyl, heteroaryl(Ci-C 2 )alkyl, aryloxy(Ci-C 2 )alkyl, heteroaryloxy(Ci-C 2 )alkyl, arylamino(Ci-C 2 )alkyl or heteroarylamino(Ci-C 2 )alkyl.
• Each of these groups is optionally substituted with one or more substituents such as halogen, cyano, hydroxy, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 4 )alkoxy(Ci-C 4 )alkoxy, hydroxy(Ci-C 4 )alkoxy, halo(Ci-C 4 )alkoxy, (C3-C8)cycloalkyl(Ci-C 4 )alkoxy, amino, (C 1 - C 4 )alkylamino, di(Ci-C 4 )alkylamino, trifluoromethylthio, (C3-Cg)cycloalkyl, pyrazolyl, pyrazolylmethyl, pyrazolylethyl, phenyl, benzyl, phenethyl, pyridyl, pyridylmethyl, phenoxy,
• R 6 in any of the embodiments of the previous paragraphs, is:
• index v is an integer selected from 0 to 3.
• index w is an integer selected from
• X is a member selected from O and N.
• Each R 10 is a member independently selected from halogen, cyano, hydroxyl and a group which is a member selected from (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (C 3 -Cg)cycloalkyl, (Ci-C 4 )alkoxy, trifluoromethylthio, phenyl, benzyl, phenethyl, phenoxy, and pyrazolyl, wherein each phenyl, benzyl, phenethyl, phenoxy, and pyrazolyl group is optionally substituted at any suitable point with one or more halogen moieties.
• R 1Oa is a member selected from H and a group which is a member selected from (C 1 - C 4 )alkyl, halo(Ci-C 4 )alkyl, phenyl, benzyl and phenethyl, wherein each phenyl, benzyl or phenethyl group is optionally substituted at any suitable point with one or more halogen moieties.
• R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are each members independently selected from H, halogen, cyano, hydroxyl, (Ci-C 4 )alkyl, hydroxy(Ci-C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 - C4)alkoxy, phenoxy, trifluoromethylthio or pyrazolyl wherein each group is optionally substituted at any suitable point with (Ci-C 4 )alkyl.
• This embodiment has the proviso that R 7 and R 7a are optionally joined with C* to form a member selected from a carbonyl and substituted and unsubstituted 3- to 7-membered ring.
• This embodiment has the further proviso that R 8 and R 8a are optionally joined with C** to form a member selected from a carbonyl and substituted and unsubstituted 3- to 7-membered ring.
• This embodiment has the further proviso that R 9 and R 9a are optionally joined with C*** to form a member selected from a carbonyl and substituted and unsubstituted 3- to 7-membered ring.
• This embodiment has the further proviso that R 7 and R 8 are optionally joined, along with the atoms to which they are attached, to form a 3- to 7-membered ring.
• This embodiment has the further proviso that R 8 and R 9 are optionally joined, along with the atoms to which they are attached, to form a 3- to 7-membered ring.
• This embodiment has the further proviso that R 7 and R 9 are optionally joined, along with the atoms to which they are attached, to form a 3- to 7-membered ring.
• This embodiment has the further proviso that R 7 and R 10 are optionally joined, along with the atoms to which they are attached, to form a 3- to 7-membered ring.
• This embodiment has the further proviso that R 8 and R 10 are optionally joined, along with the atoms to which they are attached, to form a 3- to 7-membered ring.
• This embodiment has the further proviso that R 9 and R 10 are optionally joined, along with the atoms to which they are attached, to form a 3- to 7-membered ring.
• This embodiment has the further proviso that when v is 2 or 3, each R 10 are optionally joined, along with the atoms to which they are attached, to form a 3- to 7-membered ring.
• R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are each independently selected from H, hydroxy, halogen, cyano, 2-hydroxyethyl, (S)-methyl, (R)-methyl or cyclopropyl.
• R 7 is H and R 7a is hydroxy, cyano, 2-hydroxyethyl, (S)-methyl, (R)-methyl or cyclopropyl.
• R 6 is _R9a
• R 7 and R 7a are optionally joined with C* to form a carbonyl.
• R 7 and R 7a are optionally joined with C* to form a member selected from cyclopropyl and cyclopentyl.
• C* can have an R or S configuration.
• R 8 and R 8a are optionally joined with C** to form cyclopropyl and wherein C** has a configuration which is a member selected from R and S.
• R 7 and R 8 along with the atoms to which they are attached, are optionally joined to form a member selected from cyclopropyl and tetrahydrofuran.
• R 9 and R 9a are each members independently selected from H, 2-hydroxyethyl, (S)-methyl, (R)-methyl, halogen, cyano, hydroxyl, (C 3 -C 8 )cycloalkyl, (d-C 4 )alkoxy, phenoxy, trifluoromethylthio and pyrazolyl.
• R 6 is a member selected from
• R 8 , R 8a , R 9 and R 9a are each H.
• R is a member selected from
• n each R 7 and R 7a are members independ H, methyl and hydroxy.
• R 6 is
• R 7 is hydroxy, methyl, ethyl or hydroxymethyl
• C* is in a configuration which is a member selected from R and S.
• R 8 is a member selected from hydroxy, methyl, ethyl and hydroxymethyl
• C** is in a configuration which is a member selected from R and S.
• R 7 and R 8 , along with C* and C**, are optionally joined to form a member selected from cyclopropyl, tetrahydrofuran and cyclopentyl and wherein C* and C** are each independently in a configuration which is a member selected from R and S.
• R 6 is
• R 7 and R 7a are joined with C* to form a carbonyl; and R 8 is methyl.
• R 10 is fluoro, chloro, cyano, hydroxyl, methyl, trifluoromethyl, methoxy, trifluoromethoxy, difluoromethoxy, isopropyloxy, cyclopropyl, ethoxy, pyrazol-1-yl, phenyl, chlorophenyl or chlorobenzyl.
• R 6 is
• v is 1.
• R 10 is trifluoromethoxy, trifluoromethyl, chloro or fluoro.
• R 6 is
• R 10 is trifluoromethoxy, trifluoromethyl, chloro or fluoro.
• each R 10 is a member independently selected from trifluoromethoxy, trifluoromethyl, chloro and fluoro.
• R 6 is
• R 6 is 3-chloro-4-trifluoromethoxybenzyl, 3-chloro-4-trifluoromethylbenzyl, 3- fluoro-4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3,4 dichlorobenzyl, 2,5 dichlorobenzyl, 3-chloro-4-fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3-fluoro-4- chlorobenzyl, 2-fluoro-4-trifluoromethylbenzyl, 3-cyclopropyl-4-fluorobenzyl, 2-methoxy-4- trifluoromethoxybenzyl, 3,4-difluorobenzyl, 3-fluoro-4-chlorobenzyl, 2-methyl-3- chlorobenzyl, 2-fluoro-3-trifluoromethylbenzyl or 3-trifluoromethyl-4-fluorobenzy
• R 5 is H.
• R 6 is
• B has a formula which is
• R 15 is halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy or halo(C i -C4)alkoxy .
• R , 15 is fluoro, chloro or cyano.
• B is a member selected from
• Z is thiazolyl, thiadiazolyl, isoxazolyl, tetrazolyl, triazolyl and pyrazolyl, wherein each group is optionally substituted at any suitable point with one or more substituents selected from halogen, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl or (Ci-C 4 )alkoxycarbonyl.
• Z is thiazolyl, thiadiazolyl, isoxazolyl, tetrazolyl, triazolyl and pyrazolyl, wherein each group is optionally substituted at any suitable point with one or more substituents selected from fluorine, chlorine, methyl, trifluoromethyl or methoxycarbonyl.
• Z is thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, thiadiazol-2-yl, thiadiazol-5-yl, pyrazol- 3-yl, pyrazol-4-yl, pyrazol-5-yl, isoxazol-5-yl, isoxazol-4-yl, isoxazol-3-yl, tetrazol-5-yl, triazol-3-yl or triazol-4-yl, wherein each group is optionally substituted at any suitable point with one or more substituents selected from halogen, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl or (C 1 - C 4 )alkoxycarbonyl.
• Z is 1,3 thiazolyl, 1,2,4 thiadiazolyl, 1,3,4 thiadiazolyl, isoxazolyl, 2H-tetrazolyl, 2H- 1,2, 3 triazolyl, 2H- 1,2,4 triazolyl and lH-pyrazolyl wherein each group is optionally substituted at any suitable point with one or more substituents selected from halogen, (C 1 - C 4 )alkyl, halo(Ci-C 4 )alkyl or (Ci-C 4 )alkoxycarbonyl.
• Z is 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 1,3 thiazol-5-yl, 1,3,4 thiadiazol-2-yl, 1,2,4 thiadiazol-5-yl, lH-pyrazol-3-yl, lH-pyrazol-4-yl, lH-pyrazol-5-yl, isoxazol-5-yl, isoxazol-4- yl, isoxazol-3-yl, 2H-tetrazol-5-yl, 1H-1,2,4 triazol-3-yl and -2H-1,2,3 triazol-4-yl wherein each group is optionally substituted at any suitable point with one or more substituents selected from halogen, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl or (Ci-C 4 )alkoxycarbonyl
• Z is 1,3 thiazol-2-yl, (5-chloro)l,3 thiazol-2-yl, (4-methyl)l,3 thiazol-2-yl, (5- methyl)l,3 thiazol-2-yl, 4(methoxycarbonyl)(l,3 thiazol-2-yl), 4-trifluoromethyl 1,3 thiazol-2- yl, 1,3 thiazol-4-yl, 2-methyl 1,3 thiazol-4-yl, 1,3 thiazol-5-yl, 2-methyl 1,3 thiazol-5-yl, 4- trifluoromethyl 1,3,4 thiadiazol-2-yl, 5-methyl 1,3,4 thiadiazol-2-yl, 1,3,4 thiadiazol-2-yl, 3- methyl 1,2,4 thiadiazol-5-yl, 3-ethyl 1,2,4 thiadiazol-5-yl, 1,2,4 thiazol-5-yl, 1,2,4 thi
• Z is 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl), 4-methyl(l,3 thiazol-2-yl), 5- methyl(l,3 thiazol-2-yl), 4(methoxycarbonyl)(l,3 thiazol-2-yl), 4-trifluoromethyl 1,3 thiazol-2- yl, 1,3 thiazol-4-yl, 2-methyl 1,3 thiazol-4-yl, 3-methyl 1,2,4 thiadiazol-5-yl, 3-ethyl 1,2,4 thiadiazol-5-yl or 1,2,4 thiadiazol-5-yl.
• Z is 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-(Ci-C 4 )alkyl(l,3 thiazol-2-yl) or 1,2,4 thiadiazol-5-yl.
• Z is 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-chloro(l,3 thiazol-2-yl), 5-methyl(l,3 thiazol-2-yl) or 1,2,4 thiadiazol-5-yl.
• R 5 is H.
• R 6 is 3-chlorobenzyl, 3-fluorobenzyl, 3-trifluoromethylbenzyl, 3- trifluoromethoxybenzyl, 4-chlorobenzyl, 4-fluorobenzyl, 4-trifluoromethylbenzyl, 4- trifluoromethoxybenzyl, 3-chloro-4-trifluoromethoxybenzyl, 3-chloro-4-trifluoromethylbenzyl, 3-fluoro-4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3,4 dichlorobenzyl, 2,5 dichlorobenzyl, 3-chloro-4-fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3-fluoro-4- chlorobenzyl, 2-fluoro-4-trifluoromethylbenzyl, 3-cyclopropyl-4-fluorobenzyl,
• R 5 is H
• R 6 is 3-chlorobenzyl, 3-fluorobenzyl, 3-trifluoromethylbenzyl, 3- trifluoromethoxybenzyl, 4-chlorobenzyl, 4-fluorobenzyl, 4-trifluoromethylbenzyl, 4- trifluoromethoxybenzyl, 3-chloro-4-trifluoromethoxybenzyl, 3-chloro-4-trifluoromethylbenzyl, 3-fluoro-4-trifluoromethoxybenzyl, 3-fluoro-4-trifluomethylbenzyl, 3,4 dichlorobenzyl, 2,5 dichlorobenzyl, 3-chloro-4-fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3,4 dichlorobenzyl, 2,5 dichlorobenzyl, 3-chloro-4-fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3,4 dichlorobenzyl, 2,5 dichlorobenzy
• Z is 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-(Ci-C 4 )alkyl(l,3 thiazol-2-yl) or 1,2,4 thiadiazol-5-yl.
• Z is 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-(d-C 4 )alkyl(l,3 thiazol-2-yl) or 1,2,4 thiadiazol-5-yl.
• R 5 is H.
• R 6 is 3-chlorobenzyl, 3-fluorobenzyl, 3-trifluoromethylbenzyl, 3- trifluoromethoxybenzyl, 4-chlorobenzyl, 4-fluorobenzyl, 4-trifluoromethylbenzyl, 4- trifluoromethoxybenzyl, 3-chloro-4-trifluoromethoxybenzyl, 3-chloro-4-trifluoromethylbenzyl, 3-fluoro-4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3,4 dichlorobenzyl, 2,5 dichlorobenzyl, 3-chloro-4-fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3-fluoro-4- chlorobenzyl, 2-fluoro-4-trifluoromethylbenzyl, 3-cyclopropyl-4-fluorobenzyl,
• Z is 1,3 thiazol-2-yl, 1,3 thiazol-4-yl, 5-halo(l,3 thiazol-2-yl), 5-(Ci-C 4 )alkyl(l,3 thiazol-2-yl) or 1,2,4 thiadiazol-5-yl.
• Z is 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) or 1,2,4 thiadiazol-5-yl.
• R 6 is 3-chloro-4-trifluoromethoxybenzyl, 3-chloro-4-trifluoromethylbenzyl, 3- fluoro-4-trifluoromethoxybenzyl, 3,4 dichlorobenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3- trifluoromethoxy-4-fluorobenzyl, 4-trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-fluoro- 4-chlorobenzyl, 3-chloro-4-fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3-cyclopropyl-4- fluorobenzyl, 2-methoxy-4-trifluoromethoxybenzyl, 3,4-difluorobenzyl, 2-methyl-3- chlorobenzyl, 3 -trifluoromethoxybenzyl, 2-fluoro-4-trifluoromethylbenzyl
• R 6 is 3-chloro-4-trifluoromethylbenzyl, 3-fluoro-4- trifluoromethoxybenzyl, 3 -fluoro-4-trifluoromethylbenzyl, 3 -trifluoromethoxy-4-fluorobenzyl, 3 -cyclopropyl-4-fluorobenzyl, 3 -trifluoromethyl-4-fluorobenzy 1, 2-methoxy-4- trifluoromethoxybenzyl, 2-methyl-3-chlorobenzyl, 3-trifluoromethoxybenzyl, 3-fluoro-4- trifluoromethylbenzyl, 2-fluoro-3-trifluoromethylbenzyl or 3-trifluoromethylbenzyl.
• R 6 is 3,4 dichlorobenzyl, 3-fluoro-4- trifluoromethoxybenzyl, 3-chloro-4-fluorobenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3- trifluoromethoxy-4-fluorobenzyl, 4-trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-fluoro- 4-chlorobenzyl, 3-trifluoromethyl-4-fluorobenzyl, 2-fluoro-3-trifluoromethylbenzyl, 3,4- difluorobenzyl, 3-trifluoromethoxybenzyl or 3-trifluoromethylbenzyl.
• R 6 is 3-chloro-4-trifluoromethoxybenzyl, 3-chloro- 4-trifluoromethylbenzyl, 3 -fluoro-4-trifluoromethoxybenzyl, 3 -fluoro-4-trifluoromethylbenzyl or 4-trifluoromethylbenzyl.
• Z is 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) or 1,2,4 thiadiazol-5-yl.
• R 6 is 3-chloro-4-trifluoromethoxybenzyl, 3-chloro-4-trifluoromethylbenzyl, 3- fluoro-4-trifluoromethylbenzyl, 3-fluoro-4-trifluoromethoxybenzyl, 3,4 dichlorobenzyl, 4- trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-chloro-4-fluorobenzyl, 3-fluoro-4- chlorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3,4-difluorobenzyl, 3-trifluoromethyl-4- fluorobenzyl, 3-trifluoromethoxybenzyl or 3-trifluoromethylbenzyl.
• R 6 is 3-chloro-4-trifluoromethylbenzyl, 3,4 dichlorobenzyl, 3-fluoro-4-trifluoromethoxybenzyl, 3 -fluoro-4-trifluoromethylbenzyl, 3- chloro-4-fluorobenzyl, 3-trifluoromethoxy-4-fluorobenzyl, 3,4-difluorobenzyl, 4- trifluoromethoxybenzyl, 3-trifluoromethoxybenzyl, 3-fluoro-4-chlorobenzyl or 3- trifluoromethylbenzyl.
• R 6 is 3-fluoro-4-trifluoromethylbenzyl, 3,4 dichlorobenzyl, 4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethoxybenzyl, 4- trifluoromethylbenzyl, 3-fluoro-4-chlorobenzyl, 3,4-difluorobenzyl, 3-trifluoromethyl-4- fluorobenzyl or 3-fluoro-4-trifluoromethoxybenzyl.
• R 6 is 3-chloro-4-trifluoromethoxybenzyl, 3-chloro- 4-trifluoromethylbenzyl, 3-fluoro-4-trifluoromethylbenzyl or 3-fluoro-4- trifluoromethoxybenzyl.
• B is
• Z is 1,3 thiazol-2-yl, 5-chloro(l,3 thiazol-2-yl) or 1,2,4 thiadiazol-5-yl.
• R 6 is 3,4 dichlorobenzyl, 3-fluoro-4-trifluoromethoxybenzyl, 3-chloro-4- fluorobenzyl, 4-trifluoromethoxybenzyl, 3-fluoro-4-chlorobenzyl, 4-trifluoromethylbenzyl, 3- trifluoromethoxybenzyl, 3-trifluoromethylbenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3- trifluoromethyl-4-fluorobenzyl, 3,4-difluorobenzyl or 3-trifluoromethoxy-4-fluorobenzyl.
• R 6 is 3,4 dichlorobenzyl, 3-fluoro-4- trifluoromethoxybenzyl, 4-trifluoromethoxybenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3- trifluoromethyl-4-fluorobenzyl, 3-trifluoromethylbenzyl, 3-fluoro-4-chlorobenzyl, 3,4- difluorobenzyl, 3-chloro-4-fluorobenzyl or 4-trifluoromethylbenzyl.
• R 6 is 3,4 dichlorobenzyl, 3-chloro-4- fluorobenzyl, 3-fluoro-4-chlorobenzyl, 4-trifluoromethoxybenzyl, 3-fluoro-4- trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-trifluoromethoxybenzyl, 3- trifluoromethylbenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3-trifluoromethyl-4-fluorobenzyl, 3,4- difluorobenzyl or 3-trifluoromethoxy-4-fluorobenzyl.
• B is 3,4 dichlorobenzyl, 3-chloro-4- fluorobenzyl, 3-fluoro-4-chlorobenzyl, 4-trifluoromethoxybenzyl, 3-fluoro-4- trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-trifluoromethoxybenzyl, 3- trifluoromethylbenzyl, 3-fluoro
• Z is 1,3 thiazol-2-yl, (5-chloro)l,3 thiazol-2-yl or 1,2,4 thiadiazol-5-yl.
• R 6 is 3-chloro-4-trifluoromethylbenzyl, 3-fluoro-4-trifluoromethylbenzyl, 3-fluoro- 4-trifluoromethoxybenzyl or 4-trifluoromethylbenzyl
• R 6 is 3-chloro-4-trifluoromethylbenzyl, 3-fluoro-4- trifluoromethylbenzyl or 3-fluoro-4-trifluoromethoxybenzyl.
• R 6 is 3-chloro-4-trifluoromethylbenzyl or 3- fluoro-4-trifluoromethylbenzyl.
• Z is 1,3 thiazol-2-yl, (5-chloro)l,3 thiazol-2-yl or 1,2,4 thiadiazol-5-yl.
• R 6 is 3-fluoro-4-trifluoromethoxybenzyl, 4-trifluoromethylbenzyl, 3-chloro-4- trifluoromethylbenzyl or 3,4 dichlorobenzyl.
• R 6 is 3-fluoro-4-trifluoromethoxybenzyl or 4- trifluoromethylbenzyl.
• Z is 1,3 thiazol-2-yl, (5-chloro)l,3 thiazol-2-yl or 1,2,4 thiadiazol-5-yl.
• R 6 is 3-fluoro-4-trifluoromethoxybenzyl, 3-chloro-4-trifluoromethylbenzyl or 3- fluoro-4-trifluoromethylbenzyl.
• R 6 is 3-fluoro-4-trifluoromethoxybenzyl.
• R 6 is 3-chloro-4-trifluoromethoxybenzyl, 3-chloro- 4-trifluoromethylbenzyl or 3-fluoro-4-trifluoromethylbenzyl.
• the invention is a compound of formula (I):
• R 5 and R 6 when taken together with the nitrogen to which they are attached, are joined to form a fused ring system comprising more than one ring, which is a member selected from tetrahydroindenooxazinyl, dihydroisoquinolinyl, dihydroisoindolyl and octahydromethanoindolyl.
• This fused ring system is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen, (Ci-C 4 )alkyl and aryl.
• B is aryl or 6-membered heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy and halo(Ci-C 4 )alkoxy.
• Z is a 5-membered heteroaryl, which is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxycarbonyl, (Ci-C4)alkoxy, halo(Ci-C4)alkoxy, (C3-Cg)cycloalkyl, amino, (Ci-C4)alkylamino and di(Ci- C 4 )alkylamino.
• substituents selected from the group consisting of halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxycarbonyl, (Ci-C4)alkoxy, halo(Ci-C4)alkoxy, (C3-Cg)cycloalkyl, amino, (Ci-C4)al
• R 5 and R 6 when taken together with the nitrogen to which they are attached, are members selected from (4aR,9aS)-2,3,9,9a-tetrahydroindeno[2,l-b][l,4]oxazin-4(4aH)-yl, (4aS,9aR)-2,3,9,9a-tetrahydroindeno[2,l-b][l,4]oxazin-4(4aH)-yl, 3,4-dihydroisoquinolin- 2(lH)-yl, 3,4-dihydroisoquinolin-2(lH)-yl, 5-chloro-l,3-dihydro-2H-isoindol-2-yl, 4-chloro- 1 ,3-dihydro-2H-isoindol-2-yl and (3S,3aR,6R,7aS)
• the invention is a compound of formula (I):
• R 5 is H.
• R 6 forms a fused ring system which is naphthpyridinyl, isoquinolinyl, 2,3-dihydroindenyl, 6,7- dihydrocyclopenta[b]pyridinyl or 2,3-dihydro-l-benzofuranylmethyl.
• B is aryl or 6-membered heteroaryl, each optionally substituted with one or more substituents selected from halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy or halo(Ci-C4)alkoxy.
• Z is a 5- membered heteroaryl, optionally substituted with one or more substituents selected from halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxycarbonyl, (Ci-C 4 )alkoxy, halo(Ci-C4)alkoxy, (C3-Cg)cycloalkyl, amino, (Ci-C4)alkylamino or di(Ci-C4)alkylamino.
• substituents selected from halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxycarbonyl, (Ci-C 4 )alkoxy, halo(Ci-C4)alkoxy, (C3-Cg)cycloalkyl, amino, (Ci-C4)alkylamino or di(Ci-
• R 6 is l,7-naphthpyridin-8-yl, isoquinolin-1-yl, 2,3-dihydro-lH-inden-l-yl, 6,7- dihydro-5H-cyclopenta[b]pyridin-2-yl, 2,3-dihydro-lH-inden-2-yl or 2,3-dihydro-l- benzofuran-2-ylmethyl.
• the invention is a compound of formula (I):
• R 5 and R 6 when taken together with the nitrogen to which they are attached, are joined to form morpholinyl, which is substituted with dihydroisoindolyl(Ci-C 4 )alkyl, wherein said dihydroisoindo IyI(C i-C 4 )alkyl is optionally substituted with one or more substituents selected from oxo, halogen, (Ci-C4)alkyl or aryl.
• B is a member selected from the group consisting of aryl and 6-membered heteroaryl, each optionally substituted with one or more substituents selected from halogen, cyano, (C 1 - C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy or halo(Ci-C 4 )alkoxy.
• Z is a 5-membered heteroaryl, optionally substituted with one or more substituents selected from halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxycarbonyl, (Ci-C 4 )alkoxy, halo(Ci-C 4 )alkoxy, (C 3 - Cg)cycloalkyl, amino, (Ci-C 4 )alkylamino or di(Ci-C 4 )alkylamino.
• substituents selected from halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxycarbonyl, (Ci-C 4 )alkoxy, halo(Ci-C 4 )alkoxy, (C 3 - Cg)cycloalkyl, amino, (Ci-C 4
• dihydroisoindolyl(Ci-C 4 )alkyl is l-oxo-l,3-dihydro-2H-isoindol-2-ylmethyl.
• halo(Ci-C 4 )alkyl is monohalo(Ci-C 4 )alkyl, dihalo(Ci-C 4 )alkyl or trihalo(Ci- C 4 )alkyl.
• halo(Ci-C4)alkoxy is monohalo(Ci-C4)alkoxy, dihalo(Ci-C4)alkoxy or trihalo(Ci- C 4 )alkoxy.
• R 5 and R 6 are each members independently selected from H and a group which is a member selected from (Ci-Cio)alkyl, heteroalkyl, heterocycloalkyl, heterocycloalkyl(Ci- C 2 )alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(Ci-C 2 )alkyl, aryl(d-C 2 )alkyl, aryloxy(C r C 2 )alkyl, arylamino(Ci-C 2 )alkyl, heteroaryl, heteroarylamino(Ci-C 2 )alkyl, heteroaryloxy(Ci- C 2 )alkyl and heteroaryl(Ci-C 2 )alkyl.
• Each group is optionally substituted at any suitable point with one or more substituents selected from the group consisting of oxo, halogen, cyano, hydroxy, (d-C 4 )alkyl, halo(d-C 4 )alkyl, (d-C 4 )alkoxy, (d-C 4 )alkoxy(d-C 4 )alkoxy, hydroxy(Ci-C 4 )alkyl, hydroxy(Ci-C 4 )alkoxy, halo(Ci-C 4 )alkoxy, (C 3 -C 8 )cycloalkyl(Ci- C4)alkoxy, amino, (Ci-C4)alkylamino, di(Ci-C4)alkylamino, trifluoromethylthio, (C 3 -
• Each pyrazolyl, pyrazolylmethyl, pyrazolylethyl, phenyl, benzyl, phenethyl, pyridyl, pyridylmethyl, phenoxy, phenoxymethyl, pyridyloxy or pyridyloxymethyl is optionally substituted with halogen, cyano, hydroxy, methyl, methoxy, trifluoromethyl or trifluoromethoxy.
• any of the compounds in the previous paragraphs, or pharmaceutically acceptable salts or solvates thereof, can be used as a medicament.
• the invention is a pharmaceutical formulation which includes one or more pharmaceutically acceptable excipients and a compound encompassed by any of the embodiments of the previous paragraphs.
• the invention is the use of a compound encompassed by any of the embodiments of the previous paragraphs, in the manufacture of a medicament for the treatment of a disease or condition for which a sodium channel modulator is indicated.
• exemplary diseases or conditions to be treated include pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• a compound encompassed by any of the embodiments of the previous paragraphs is used in the treatment of pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention is the use of a compound encompassed by any of the embodiments of the previous paragraphs, or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention provides a method of ameliorating or alleviating a condition in a subject.
• This condition is pain, irritable bowel syndrome, Crohn's disease and/or tachyarrhythmia.
• This method includes administering to a subject an amount of a compound encompassed by any of the embodiments of the previous paragraphs, in an amount sufficient to ameliorate or alleviate the condition.
• the invention is a compound described herein. In an exemplary embodiment, the invention is a compound described in the Examples.
• compounds of the invention that are poly- or multi-valent species, including, for example, species such as dimers, trimers, tetramers and higher homo logs of the compounds of the invention or reactive analogues thereof.
• the poly- and multi-valent species can be assembled from a single species or more than one species of the invention.
• a dimeric construct can be "homo-dimeric” or "heterodimeric.”
• poly- and multi-valent constructs in which a compound of the invention or a reactive analogue thereof, can be attached to an oligomeric or polymeric framework e.g., polylysine, dextran, hydroxyethyl starch and the like
• the framework is preferably polyfunctional (i.e. having an array of reactive sites for attaching compounds of the invention).
• the framework can be derivatized with a single species of the invention or more than one species of the invention.
• the present invention includes compounds within a motif described herein, which are functionalized to afford compounds having water-solubility that is enhanced relative to analogous compounds that are not similarly functionalized.
• any of the substituents set forth herein can be replaced with analogous radicals that have enhanced water solubility.
• additional water solubility is imparted by substitution at a site not essential for the activity towards the ion channel of the compounds set forth herein with a moiety that enhances the water solubility of the parent compounds.
• Such methods include, but are not limited to, functionalizing an organic nucleus with a permanently charged moiety, e.g., quaternary ammonium, or a group that is charged at a physiologically relevant pH, e.g. carboxylic acid, amine.
• Other methods include, appending to the organic nucleus hydroxyl- or amine-containing groups, e.g. alcohols, polyols, polyethers, and the like.
• Representative examples include, but are not limited to, polylysine, polyethyleneimine, poly(ethyleneglycol) and poly(propyleneglycol). Suitable functionalization chemistries and strategies for these compounds are known in the art. See, for example, Dunn, R. L., et al, Eds. Polymeric Drugs and Drug Delivery Systems, ACS Symposium Series Vol. 469, American Chemical Society, Washington, D.C. 1991.
• PG a suitable nitrogen protecting group, preferably 2, 4-dimethoxybenzyl
• R H, (Ci-Cio)alkyl, aryl, aryl(Ci-C 2 )alkyl
• compounds of formula (III) may be prepared from compounds of formula (II) according to reaction step (i), an amide coupling between R 5 R 6 NH and the acid chloride formed from compounds of formula (II) in the presence of excess organic base such as triethylamine, pyridine, 2,6-lutidine or Hunig's base, in a suitable solvent, at temperatures of - 78 0 C to room temperature.
• the acid chloride may be prepared by reaction of a compound of formula (II) with a suitable agent such as oxalyl chloride-catalytic DMF or thionyl chloride. Typical conditions comprise oxalyl chloride-catalytic DMF in DCM at O 0 C.
• compounds of formula (III) may be prepared from compounds of formula (XVII), as shown in Scheme 4 illustrated below.
• Compounds of formula (I) may be prepared from compounds of formula (III) according to reaction step (ii), displacement of a leaving group with H 2 NZ under basic reaction conditions, for example, pyridine, Et 3 N, DABCO or Hunig's base, optionally in the presence of a co-solvent such as DCM, at temperatures of 0 to 6O 0 C. Typical conditions comprise reaction in pyridine at room temperature for 16 hours.
• Compounds of the formula (IV) may be prepared from compounds of the formula (III) according to reaction step (iii), displacement of a leaving group with PG(H)NZ, wherein PG is a suitable N-protecting group. Any suitable nitrogen protecting group may be used (as described in "Protecting Groups in Organic Synthesis” 3 rd edition T. W. Greene and P. G. Wuts, Wiley-Interscience, 1999).
• Common nitrogen protecting groups (PG) suitable for use include tert-butoxycarbonyl (t-Boc) (which is readily removed by treatment with an acid such as TFA or hydrogen chloride in an organic solvent such as DCM or 1,4-dioxane), and benzyl (which is readily removed by hydrogenation in the presence of a suitable catalyst, or by treatment with 1-chloroethyl chloro formate).
• Step (iii) is carried out in the presence of a strong base, for example LiHMDS or NaH in a suitable solvent such as THF.
• Typical conditions comprise LiHMDS in THF at temperatures of -78 to O 0 C.
• PG is 2, 4- dimethoxybenzyl.
• Compounds of the formula (I) may be prepared from compounds of the formula (IV) according to reaction step (iv), deprotection of the N-protecting group (PG).
• PG N-protecting group
• typical deprotection conditions comprise HCl in an appropriate solvent such as dioxane, ether, water or TFA in DCM at room temperature.
• PG a suitable nitrogen protecting group, preferably 2, 4-dimethoxybenzyl
• R H, (Ci-Cio)alkyl, aryl, aryl(Ci-C 2 )alkyl
• Compounds of formula (V) can be prepared from compounds of formula (II) according to reaction step (iii) as previously described.
• Compounds of formula (VI) may be prepared from compounds of formula (V) according to reaction step (iv) as previously described.
• R is not H compounds of formula (VI) may be prepared from compounds of formula (II) according to reaction step (ii) as previously described.
• R is not H compounds of formula (VII) may be prepared from compounds of formula (V) according to reaction step (v), ester hydrolysis using conventional procedures, typically under aqueous basic conditions, for example in the presence of sodium hydroxide, potassium hydroxide or lithium hydroxide in an inert solvent such as MeOH, EtOH, ethylene glycol, THF, DME, and 1,4-dioxane. Preferred conditions comprise aqueous sodium or lithium hydroxide in dioxane or MeOH at room temperature.
• R is H compounds of formula (VIII) can be prepared from compounds of formula (V) according to reaction step (iv) as previously described.
• R is H compounds of formula (VI) compounds of formula (VIII).
• R is not H compounds of formula (VIII) can be prepared from compounds of formula (VI) according to reaction step (v) as previously described.
• Compounds of formula (VIII) can be prepared from compounds of formula (VII) according to reaction step (iv) as previously described.
• Compounds of formula (IV) may be prepared from compounds of formula (VII) according to reaction step (i), as previously described, or by reaction step (vi) an amide coupling with R 5 R 6 NH via activation of the carboxylic acid by a suitable agent such as HBTU, WSCDI or DCC, optionally in the presence of a catalyst for example HOBT or HOAT, and optionally in the presence of a tertiary amine base for example JV-methylmorpholine, Et 3 N or N,N-diisopropylethylamine in a suitable solvent such as DMF, THF, DMSO, DMA, at 10-40 0 C for 0.5-48 hours.
• Typical conditions comprise activation through TBTU in DCM or DMF in the presence OfEt 3 N at room temperature for 0.5-16 hours.
• Compounds of formula (I) may be prepared from compounds of formula (VIII) according to reaction steps (i) or (vi), as previously described.
• Compounds of formula (I) may be prepared from compounds of formula (IV) according to reaction step (iv), as previously described.
• LG and LG' are independently a suitable leaving group, for example F, Cl, Br or OR" where
• R" (Ci-Cio)alkyl, aryl, aryl(Ci-C 2 )alkyl
• R H, (Ci-Cio)alkyl, aryl, aryl(Ci-C 2 )alkyl
• G a group capable of a functional group interconversion to an acid for example CH 3 , CN
• Compounds of formula (XI) may be prepared from compounds of formula (X) according to reaction step (vii),displacement of a leaving group with a sulphur nucleophile for example benzylmercaptan, under basic reaction conditions for example in the presence of potassium carbonate, cesium carbonate or Et 3 N, in a suitable solvent, for example DMSO, DMF.
• a suitable solvent for example DMSO, DMF.
• Typical conditions comprise benzylmercaptan in the presence of cesium carbonate in DMSO at 70-80 0 C for 3 hours.
• Compounds of formula (XII) may be prepared from compounds of formula (X) according to reaction step (viii) a functional group interconversion to afford an acid.
• G is CH 3
• an oxidation reaction is carried out using an appropriate oxidising agent, for example eerie ammonium nitrate or chromyl chloride. Typical conditions comprise excess potassium permanganate in the presence of excess aqueous KOH at 90 0 C for 3-4 hours.
• G is CN
• a hydrolysis reaction is carried out using conventional procedures, under basic or acidic conditions, for example in the presence of sodium hydroxide and hydrogen peroxide or sulphuric acid. Typical conditions comprise refluxing in concentrated HCl or in NaOH.
• compounds of formula (XII) may be commercially available.
• Compounds of the formula (XIII) may be prepared from compounds of the formula (XII) according to reaction step (vii) or from compounds of the formula (XI) according to reaction step (viii) as previously described.
• Compounds of the formula (II) may be prepared from compounds of the formula (XIV) according to reaction step (xi), a diazotisation using an appropriate source of nitrous acid, for example H2SO4/HNO3, followed by displacement of the intermediate diazonium salt with sulphur dioxide in the presence of a copper catalyst and chloride source.
• Typical conditions comprise sodium nitrite in HCl followed by sulphur dioxide in the presence of copper (I) chloride in AcOH.
• Compounds of formula (II) may be prepared from compounds of formula (XIII) according to reaction step (ix), an oxidation to the sulfonyl chloride using an appropriate agent such as AcOH/chlorine or aq bleach/HCl. Typical conditions comprise aq bleach/HCl at O 0 C.
• Compounds of the formula (XVI) may be prepared from compounds of the formula (XII) according to reaction step (ii) or (iii) as previously described.
• Compounds of the formula (XVII) may be prepared from compounds of the formula (XVI) according to reaction step (vii) as previously described.
• Compounds of the formula (III) may be prepared according to reaction step (ix), an oxidation to the sulfonyl chloride using an appropriate agent such as AcOH/chlorine or aqueous bleach/HCl.
• Typical conditions comprise aqueous bleach/HCl at 0 0 C.
• LG is OR
• Typical conditions comprise pentafluorophenol in the presence OfEt 3 N in DCM at room temperature.
• Compounds of formula (XIX) may be prepared from compounds of formula (XVIII) using the conditions of step (ii) as previously described.
• Compounds of formula (I) may be prepared from compounds of formula (XIX) according to reaction step (xii), a metal-catalyzed carbonyl-insertion amide forming reaction using palladium acetate, hexacarbonylmolybdenum, sodium carbonate, a solvent such as water or dioxane, and microwave irradiation (Wu et al., Organometallics 25, 1434 (2006)).
• the activity of sodium channels can be assessed using a variety of in vitro assays, including but not limited to, measuring ion flux, measuring transmembrane potential, and/or measuring ionic current. Measurement of ionic fluxes can be accomplished by measuring changes in the concentration of the permeant species or by tracking the movement of small amounts of an appropriately permeant radioactive tracer. Transmembrane potential can be assessed with voltage-sensitive fluorescent dyes or, more sensitively, with electrophysiological methods.
• Determination of the effectiveness of compounds as ex vivo blockers of sodium channels can be assessed by the inhibition of compound action potential propagation in isolated nerve preparations (Kourtney and Stricharz, LOCAL ANESTHETICS, Springer- Verlag, New York, 1987).
• a number of experimental models in the rat are appropriate for assessing the in vivo efficacy of the compounds of the invention.
• the neuropathic pain model produced by the tight ligation of spinal nerves described by Kim et ah, Pain, 50: 355-363 (1992)
• Mechanical sensitivity can also be assessed using a procedure described by Chaplan et al., J. Neurosci. Methods, 53: 55-63 (1994). Other assays of use are known to those of skill in the art.
• TTX-sensitive sodium channels can be tested using biologically active recombinant channels, or naturally occurring TTX-sensitive sodium channels, or by using native cells, like neurons expressing a TTX-sensitive sodium current.
• TTX-sensitive sodium channels can be isolated, co-expressed or expressed in a cell, or expressed in a membrane derived from a cell.
• TTX-sensitive sodium channels are generally expressed alone to form a homomeric sodium channel or may be co-expressed with a second subunit ⁇ e.g., an auxiliary beta subunit) so as to form a heteromeric sodium channel.
• the TTX- sensitive sodium channels are stably expressed in HEK-293 cells, an example of an effective mammalian expression system.
• Modulation can be tested using one of the in vitro or in vivo assays described above. Samples or assays that are treated with a potential sodium channel inhibitor are compared to control samples without the test compound, to examine the extent of modulation. Control samples (untreated with inhibitors) are assigned a relative sodium channel activity value of 100. Inhibition of TTX-sensitive sodium channels is achieved when the sodium channel activity value relative to the control is less than 70%, preferably less than 40% and still more preferably, less than 30%. Compounds that decrease the flux of ions will cause a detectable decrease in the ion current density by decreasing the probability of a TTX-sensitive sodium channel being open, by decreasing conductance through the channel, decreasing the number of channels, or decreasing the expression of channels.
• Changes in ion flux may be assessed by determining changes in polarization (i.e., electrical potential) of the cell or membrane expressing the sodium channel.
• a preferred means to determine changes in cellular polarization is by measuring changes in current or voltage with the voltage-clamp and patch-clamp techniques, using the "cell-attached” mode, the "inside -out” mode, the “outside-out” mode, the “perforated patch” mode, the "whole cell” mode or other means of controlling or measuring changes in transmembrane potential (see, e.g., Ackerman et al, New Engl. J. Med., 336: 1575-1595 (1997)).
• Assays for compounds capable of inhibiting or increasing sodium flux through the channel proteins can be performed by application of the compounds to a bath solution in contact with and comprising cells having a channel of the present invention (see, e.g., Blatz et al., Nature 323: 718-720 (1986); Park, J. Physiol. 481: 555-570 (1994)).
• the compounds to be tested are present in the range from about 1 nM to about 100 mM, preferably from about 1 nM to about 30 ⁇ M. In an exemplary embodiment, the compounds to be tested are present in the range from about 1 nM to about 3 ⁇ M.
• the effects of the test compounds upon the function of the channels can be measured by changes in the electrical currents or ionic flux or by the consequences of changes in currents and flux.
• Changes in electrical current or ionic flux are measured by either increases or decreases in flux of ions such as sodium or guanidinium ions (see U.S. Patent No. 5,688,830).
• the cations can be measured in a variety of standard ways. They can be measured directly by concentration changes of the ions or indirectly by membrane potential or by using radioactive ions. Consequences of the test compound on ion flux can be quite varied. Accordingly, any suitable physiological change can be used to assess the influence of a test compound on the channels of this invention.
• test compound can be measured by a toxin-binding assay.
• functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as transmitter release, hormone release, transcriptional changes to both known and uncharacterized genetic markers, changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as Ca 2+ , or cyclic nucleotides.
• High throughput screening is of use in identifying promising candidate compounds of the invention.
• an agent that modifies the gating of the channel e.g., pyrethroids, alpha-scorpion toxins, beta-scorpion toxins, batrachotoxin, etc.
• agents modify the gating of sodium channels and keep the pore open for extended periods of time.
• sodium channels are primarily selective for sodium, other ionic species can permeate the channel.
• TTX-sensitive sodium channel blocking agents of the invention can also be assayed against non-specific blockers of sodium channels, such as tetracaine, mexilitine, and flecainide.
• the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound of the invention described herein.
• the invention provides a pharmaceutical formulation comprising a pharmaceutically acceptable excipient and a compound according to a formula described herein.
• the invention provides a pharmaceutical formulation comprising a pharmaceutically acceptable excipient and a compound according to Formula I.
• a compound of the invention described herein, or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament in an exemplary embodiment, a compound according to a formula described herein, or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament.
• a compound according to formula I, or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament in an exemplary embodiment, a compound according to formula I, or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament.
• the invention provides a pharmaceutical formulation including a compound of the invention described herein, and one or more pharmaceutically acceptable excipients.
• the invention provides a pharmaceutical formulation including a compound according to a formula described herein, and one or more pharmaceutically acceptable excipients.
• the invention provides a pharmaceutical formulation including a compound according to formula I, and one or more pharmaceutically acceptable excipients.
• the invention provides the use of the compound of the invention described herein, in the manufacture of a medicament for the treatment of a disease or condition for which a sodium channel modulator is indicated, preferably pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention provides the use of the compound according to a formula described herein, in the manufacture of a medicament for the treatment of a disease or condition for which a sodium channel modulator is indicated, preferably pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention provides the use of the compound according to formula I, in the manufacture of a medicament for the treatment of a disease or condition for which a sodium channel modulator is indicated, preferably pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention provides a compound of the invention described herein, for use in the treatment of pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention provides a compound according to a formula described herein, for use in the treatment of pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention provides a compound according to formula I, for use in the treatment of pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention provides the use of a compound of the invention described herein, or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention provides the use of a compound according to a formula described herein, or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the invention provides the use of a compound according to formula I, or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the compounds of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms.
• the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, subdural, epidural, or intraperitoneally.
• the compounds described herein can be administered by inhalation, for example, intranasally.
• the compounds of the present invention can be administered transdermally.
• the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and either a compound described herein, or a pharmaceutically acceptable salt of a compound described herein.
• pharmaceutically acceptable carriers can be either solid or liquid.
• Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
• a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
• the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
• the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
• the powders and tablets preferably contain from 5% or 10% to 70% of the active compound.
• Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
• the term "preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
• cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
• a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
• the active component is dispersed homogeneously therein, as by stirring.
• the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
• Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
• liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
• Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired.
• Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
• viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
• solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
• the pharmaceutical preparation is preferably in unit dosage form.
• the preparation is subdivided into unit doses containing appropriate quantities of the active component.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
• the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
• the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component.
• the composition can, if desired, also contain other compatible therapeutic agents.
• the invention provides a method of modulating the activity of a voltage-gated sodium channel in a subject or a biological media.
• This method comprises administering to a subject or biological media an amount of a compound according a formula described herein sufficient to modulate said activity.
• the method comprises administering to a subject or a biological media an amount of a compound described herein sufficient to modulate said activity.
• This method comprises administering to a subject or a biological media an amount of a compound according a formula described herein sufficient to modulate said activity.
• the method comprises administering to a subject or a biological media an amount of a compound according to Formula I sufficient to modulate said activity.
• the present invention provides methods for decreasing ion flow through voltage gated sodium channels in a cell, comprising contacting a cell containing the target ion channels with a sodium channel-inhibiting amount of a compound described herein.
• the voltage-gated sodium channel which is substantially inhibited is NaVl .3.
• the methods provided in this aspect of the invention are useful for the diagnosis of conditions that can be treated by inhibiting ion flux through voltage gated sodium channels, or for determining if a patient will be responsive to therapeutic agents, which act by inhibiting sodium channels.
• Inhibition 0fNaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8 or NaVl .9 activity in a biological media is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium ion channels in biological and pathological phenomena; and the comparative evaluation of new sodium ion channel inhibitors.
• the invention provides a method of ameliorating or alleviating a condition in a subject.
• the condition can be a member selected from pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia.
• the method includes administering to the subject an effective amount of a compound described herein and/or according to a formula described herein (for example, formula I) sufficient to ameliorate or alleviate the condition.
• the compounds provided herein are used to treat a disorder or condition by inhibiting an ion channel of the VGSC family.
• the compounds provided herein are used to treat a disorder or condition by inhibiting NaV 1.1 or NaV 1.3.
• the invention provides a method of ameliorating or alleviating a condition in a subject, wherein said condition is a member selected from pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia, said method including administering to said subject an amount of a compound of the invention described herein, sufficient to ameliorate or alleviate said condition.
• the invention provides a method of ameliorating or alleviating a condition in a subject, wherein said condition is a member selected from pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia, said method including administering to said subject an amount of a compound of a formula described herein, sufficient to ameliorate or alleviate said condition.
• the invention provides a method of ameliorating or alleviating a condition in a subject, wherein said condition is a member selected from pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia, said method including administering to said subject an amount of a compound of formula I, sufficient to ameliorate or alleviate said condition.
• the invention provides a method of ameliorating or alleviating a condition in a subject, wherein said condition is a member selected from pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia, said method including administering to said subject an amount of a compound of the invention described herein, sufficient to ameliorate or alleviate said condition.
• the invention provides a method of ameliorating or alleviating a condition in a subject, wherein said condition is a member selected from pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia, said method including administering to said subject an amount of a compound of a formula described herein, sufficient to ameliorate or alleviate said condition.
• the invention provides a method of ameliorating or alleviating a condition in a subject, wherein said condition is a member selected from pain, irritable bowel syndrome, Crohn's disease and tachyarrhythmia, said method including administering to said subject an amount of a compound of Formula I, sufficient to ameliorate or alleviate said condition.
• the condition is pain
• the pain can be a member selected from acute pain, chronic pain, visceral pain, inflammatory pain and neuropathic pain. Exemplary aspects of this method are described in greater detail herein.
• the compounds of the invention are particularly preferred for use in the treating, preventing or ameliorating pain.
• the method includes administering to a patient in need of such treatment, a therapeutically effective amount of a compound described herein and/or according to a formula described herein, or a pharmaceutically acceptable salt thereof.
• the compounds, compositions and methods of the present invention are of particular use in treating pain, including both inflammatory and neuropathic pain.
• Exemplary forms of pain treated by a compound of the invention include, postoperative pain, osteoarthritis pain, pain associated with metastatic cancer, neuropathy secondary to metastatic inflammation, trigeminal neuralgia, glossopharangyl neuralgia, adiposis dolorosa, burn pain, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, burn pain, pain following stroke, thalamic lesions, radiculopathy, and other forms of neuralgic, neuropathic and idiopathic pain syndromes.
• Idiopathic pain is pain of unknown origin, for example, phantom limb pain.
• Neuropathic pain is generally caused by injury or infection of the peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation and vasculitis.
• Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies.
• the compounds utilized in the method of the invention are administered at the initial dosage of about 0.001 mg/kg to about 1000 mg/kg daily.
• a daily dose range of about 0.1 mg/kg to about 100 mg/kg is more typical.
• the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound.
• the dosage is increased by small increments until the optimum effect under the circumstances is reached.
• the total daily dosage may be divided and administered in portions during the day, if desired.
• MS mass spectra
• ESI electrospray ionization
• APCI atmospheric pressure chemical ionization
• CDCl 3 deuterochloroform
• Cl 6 -DMSC deuterodimethylsulphoxide
• CD3OD deuteromethanol
• THF tetrahydrofuran
• the material was purified by chromatography using an Isco silica cartridge eluting with 90:10 DCM: MeOH then further purified by tritutation with diethyl ether and ethyl acetate.
• the title compound was obtained as a pink solid (55mg, 0.115mmol, 11%).
• Amines used for the amide bond formation are commercially available, synthesized via known literature methods (referenced in table) or synthesized by analogous methods known to those skilled in the art.
• Amines used for the amide bond formation are commercially available, synthesized via known literature methods (referenced in table) or synthesized by analogous methods known to those skilled in the art.
• the reaction mixture was stirred at 0 0 C for 20 minutes before the addition of 4- (trifluoromethoxy)benzylamine (36 ⁇ L, 0.23mmol, l.leq) and then stirred for a further 18 hours.
• the solvent was evaporated in vacuo and the residue partitioned between DCM (15ml) and water (15ml) then passed through a phase separation cartridge.
• the organic phase was concentrated and the residue redissolved in 4.5M HCl in 1,4-dioxane (5ml) and the solution stirred at room temperature for 18 hours.
• the solvent was evaporated in vacuo and the residue purified by preparative HPLC to yield the title compound.
• reaction mixture was extracted from 2M HCl into DCM, dried over sodium sulphate, filtered and evaporated.
• the crude material was purified by column chromatograpy eluting with DCM: MeOH (95:5) to yield the title compound (72mg, 0.136mmol, 22%).
• the reaction mixture was diluted with ethyl acetate (10ml), washed with water (10ml), sat sodium hydrogen carbonate (10ml), dried over sodium sulphate, filtered and evaporated in vacuo.
• the crude material was purified by column chromatography eluting with 0-100% DCM:MeOH:AcOH (95:5:0.5). The obtained compound was further triturated in DCM and filtered to yield the title compound (50.1mg, 0.092mmol, 42%).
• the reaction mixture was diluted with ethyl acetate (10ml), washed with water (10ml), sat sodium hydrogen carbonate (10ml), dried over sodium sulphate, filtered and evaporated in vacuo.
• the crude material was purified by preparative HPLC to yield the title compound.
• the reaction mixture was stirred at room temperature for 18 hours.
• the mixture was extracted from water into DCM, dried over magnesium sulphate, filtered and evaporated in vacuo.
• the residue was dissolved in 4M HCl in dioxane (2ml) and the reaction mixture stirred at room temperature for 18 hours.
• the resulting precipitate was collected by filtration and washed with dioxane.
• the material was purified further by preparative HPLC to yield the title compound.
• reaction mixture was stirred at 30-40 0 C for 18 hours.
• the reaction mixture was extracted from 2M HCl into ethyl acetate, washed with sat sodium hydrogen carbonate, brine, dried over magnesium sulphate, filtered and evaporated in vacuo.
• the crude material was purified by preparative HPLC to yield the title compound.
• the reaction mixture was diluted with ethyl acetate (10ml), washed with water (10ml), sat sodium hydrogen carbonate (10ml), dried over sodium sulphate, filtered and evaporated in vacuo.
• the crude material was purified by column chromatography eluting with 0-100% DCM: MeOH: AcOH (95:5:0.5). The obtained compound was further triturated in DCM and filtered to yield a white solid (30mg, O.O ⁇ lmmol, 31%).
• reaction was chromatographed (12 g silica gel column, hexanes to ethyl acetate gradient elution) and product fractions were combined and evaporated to a residue.
• the residue was dissolved in methylene chloride and TFA (0.25mL) was added.
• the reaction was allowed to stir for 3 hours.
• the reaction was concentrated onto Celite and purified by column chromatography (4g silica gel column, hexanes to 10% MeOH in ethyl acetate graidient elution). Product fractions were combined and evaporate to give product as a white solid (19 mg, 33%)
• Solvent A 7800 water/200 acetonitrile/8 TFA.
• Solvent B 7200 acetonitrile/800 water/8 TFA). The product containing fractions were lyophilized to afford the product as a white powder (37 mg, 15 %).
• reaction mixture was diluted with 1 N HCl and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was taken up in 1.2 mL of DMSO, filtered, and purified via HPLC (Prep: Phenomenex 250 x 30.0 mm 15 micron C18 column. 40 niL/min. Gradient 15% B to 100% B over 25 min. Solvent A: 7800 water/200 acetonitrile/8 TFA. Solvent B: 7200 acetonitrile/800 water/8 TFA).
• the intermediate was taken up in methylene chloride (5.0 mL, 78 mmol) and TFA (500 ⁇ L, 6 mmol) was added. After stirring 30 min, the reaction mixture was diluted with ether and concentrated onto Celite. The residue was purified via automated flash chromatography (12 g SiO 2 , chloroform to 20% MeOH in chloroform). The product containing fractions were concentrated onto Celite and re-purified via automated flash chromatography (12 g SiO 2 , hexanes to 10% MeOH in ethyl acetate) to afford the product as a white solid.
• TFA 750 ⁇ L, 9.7 mmol
• 6- ⁇ [(2,4-dimethoxybenzyl)(l ,3- thiazol-2-yl)amino]sulfonyl ⁇ -N-[4-(trifluoromethyl)benzyl]nicotinamide Preparation 88, 1.15 g, 1.94 mmol
• methylene chloride 12 mL, 180 mmol
• the residue was purified on the Isco (12O g SiO 2 cartridge, chloroform to 12% MeOH in chloroform). The appropriate fractions were concentrated in vacuo. The residue was treated with acetonitrile, generating a white precipitate. The volume was reduced in vacuo, and the solids were collected via filtration, washing with acetonitrile. The off-white product was dried under vacuum (428 mg, 47%).
• the resulting solid was triturated with methylene chloride and ether.
• the resulting solid was purified on the Gilson (Semi-prep: Phenomenex 100 x 21.2 mm 10 micron C18 column. 20 mL/min. Gradient 15% B to 100% B over 25 min.
• Solvent A 7800 water/200 acetonitrile/8 TFA.
• Solvent B 7200 acetonitrile/800 water/8 TFA) to afford the title compound (39 mg, 20%).

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Hydrogenated Pyridines (AREA)

Priority Applications (2)

Applications Claiming Priority (4)

Publications (1)

Family

ID=39788940

Family Applications (1)

Country Status (14)

Cited By (76)

Families Citing this family (17)

Citations (2)

Family Cites Families (42)

• 2008
  • 2008-03-20 CA CA2681572A patent/CA2681572C/en not_active Expired - Fee Related
  • 2008-03-20 EP EP08153165A patent/EP1995241B1/en active Active
  • 2008-03-20 DE DE602008000809T patent/DE602008000809D1/de active Active
  • 2008-03-20 ES ES08153165T patent/ES2340640T3/es active Active
  • 2008-03-20 US US12/052,593 patent/US8357711B2/en not_active Expired - Fee Related
  • 2008-03-20 CL CL200800835A patent/CL2008000835A1/es unknown
  • 2008-03-20 WO PCT/US2008/057730 patent/WO2008118758A1/en not_active Ceased
  • 2008-03-20 JP JP2010501112A patent/JP5361857B2/ja not_active Expired - Fee Related
  • 2008-03-20 AT AT08153165T patent/ATE461177T1/de not_active IP Right Cessation
  • 2008-03-21 TW TW097110261A patent/TW200845969A/zh unknown
  • 2008-03-24 UY UY30978A patent/UY30978A1/es not_active Application Discontinuation
  • 2008-03-24 PE PE2008000533A patent/PE20090237A1/es not_active Application Discontinuation
  • 2008-03-24 PA PA20088773501A patent/PA8773501A1/es unknown
  • 2008-03-25 AR ARP080101215A patent/AR065824A1/es not_active Application Discontinuation
• 2012
  • 2012-11-15 US US13/677,849 patent/US8741934B2/en not_active Expired - Fee Related

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events